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نیدقت ،ِت يیها رفَلیًٍ 
 
 
يه ُرگ نّاَخ ،دز ىاوشچ ار ات ،دیشرَخ لد اّ ار ات ،قشع ِیاس اّ ار ات ،بآ ِخاش اّ ار ات دات. 
رّ ِچ ماٌشد زا ةل اّ نّاَخ دیچرت. 
ِچرّ ،راَید زا اج نّاَخ رت دٌک. 
یتشآ نّاَخ داد. 
اٌشآ نّاَخ درک. 
ُار نّاَخ تفر. 
رًَ نّاَخ درَخ. 
تسٍد نّاَخ تشاد . 
بارْس یرْپس 
 
I shall graft eyes to the sun, hearts to love, shadows to water and branches to the wind 
I shall remove every obscenity from the lips 
I shall remove every wall from the root 
I shall reconcile 
I shall familiarize 
I shall eat light 
I shall love  
 
Sohrab Sepehri 
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General Introduction
Aim and Outline of
this Thesis
The need to carry out many assays simultaneously in biomedical research has 
promoted the development of multiplexing technologies. The main goal of “multiplexing” is 
the rapid and simultaneous screening of (a) biological samples (in the clinical biology) and/or 
(b) large libraries of chemical compounds for their binding to target molecules (in drug 
discovery programs). As explained in Chapter 1 of this thesis, multiplex assays can be 
performed on "positional arrays" or on "non positional arrays". In non positional cellular
arrays cells are grown on encoded micron sized carriers; the biological activity of the 
compounds are screened in the cells that are growing at the surface of the carriers; the code 
of the microcarrier allows one to know which cell type is present at its surface.
Recently our group has introduced photophysically encoded microparticles named 
“Memobeads”. The major aim of this thesis is to investigate the applications of these 
microparticles. First we investigate to which extent Memobeads could be of use in non 
positional cellular array technologies. Later they were evaluated for a totally different 
purpose, namely as a tool to protect pharmaceutical products from counterfeiting.
In Chapter 1 the main nucleic acid delivery systems are summarized and an overview 
is given on multiplexing technologies that allow screening of different compounds against a
large numbers of targets. Additionally, “reverse transfection” and its use in cell microarrays 
are discussed. Finally, digitally encoded microparticles are introduced. 
In Chapter 2 the physicochemical and transfection properties of cationic 
hydroxyethylcellulose/plasmid DNA (pDNA) nanoparticles are investigated and compared 
with the properties of DNA nanoparticles based on polyethylene imine (PEI) which is widely 
investigated as gene carrier. 
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Chapter 3 shows how digitally encoded microparticles can be loaded with different 
kinds of cells, keeping the digital code in the microcarriers readable. Also the possibility to 
perform ELISA’s on cells that grow on the encoded microcarriers is shown. 
It is further shown in Chapter 4 that, after optimizing the surface, encoded beads are 
suitable for immobilizing viral vectors or nucleic acids, either in naked form or complexed. 
We showed that cells growing at the surface of the beads could become transduced with 
adenoviral particles.
Finally, Chapter 5 shows that Memobeads may become a major tool in combating 
counterfeiters of pharmaceuticals, by incorporating the encoded microcarriers in drug 
tablets.
INTRODUCTION- CHAPTER 1
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ABSTRACT
The technology of gene transfection has become more and more important because 
of its application in therapeutic and basic research. Subsequently, this has led to the 
development of many different transfection techniques, all aiming to efficiently introduce 
genetic materials into host cells. Generally, two systems can be distinguished, viral and non-
viral. Both of these methods have advantages and disadvantages. This chapter gives an 
overview of these methods.
The genetic materials, either in free form or complexed with chemical reagents, can 
be delivered to the cells by direct administration or after immobilization on a solid surface. 
Immobilizing nucleic acids onto the surface of a culture substrate prior to cell seeding, 
termed reverse transfection, has different applications than the traditional gene delivery 
approach such as transfected cell microarrays and tissue engineering. 
Several approaches have been employed for nucleic acid immobilization on solid 
surface. Multilayered polyelectrolyte films are one of the possibilities not only to immobilize 
nucleic acid on solid surface but also to control its delivery. We introduced encoded 
microcarriers to use as a non-positional microarray for reverse transfection and also other 
molecular analysis.
INTRODUCTION- CHAPTER 1
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INTRODUCTION
Gene Delivery
Gene delivery is a promising technology that has numerous applications in both basic 
and applied science such as gene therapy, tissue engineering, and transfected cell arrays. 
This method with high potential for treating chronic diseases and genetic disorders has 
drawn a lot of attention. Gene therapy involves the delivery of (a) DNA that encodes for an 
absent protein, to cells and/or (b) siRNA or antisense oligonucleotides to knock down 
unwanted or deregulated proteins 1-4.
Due to rapid degradation by the nucleases, its large size and its high negative charge, 
naked DNA is not really suitable for gene delivery though it has been shown that muscle cells 
can become transfected with naked DNA 5. Especially, the membrane of cells is negatively 
charged and naked DNA can not interact with the cell membrane. Because of these 
limitations, to enhance the internalization of DNA into the cell, it is necessary to use DNA-
carrier complexes. Development of efficient and safe delivery systems is really critical for 
successful gene transfer.
An efficient gene delivery system should overcome different extracellular and 
intracellular (Fig 1) barriers. These barriers include: (a) polynucleotide degradation in 
extracellular space, (b) internalization of the carrier, (c) intracellular trafficking from 
endosome to the lysosome, (d) dissociation of the polynucleotides from the carrier and (e) 
entry of the polynucleotides into the nucleus. For in vivo applications, many other factors,
including the physicochemical properties of the carrier in the blood and its immunological 
properties should be considered as well 6.
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Gene delivery systems can be categorized in two types: viral 7-10 and non-viral 
transfection 11-15 systems. Viruses are powerful gene transfer agents but there still remain 
concerns about insertional mutagenesis, immunogenicity and cytotoxicity of this system 16-
21. In contrast, non viral systems are much safer and additionally have less limitation in the 
molecular size of the DNA they have to carry 22. However, low transfection efficiency 
seriously limits this method. To improve this low efficiency, several cationic liposome 23-25
and cationic polymers 26-32 have been investigated in different research programmes. The 
ideal vector should (1) be non-immunogenic (2) show high transfection/transduction; (3) 
allow controlled and targeted transgene expression and (4) be cheap. 
Gene delivery must be selected according to the specific therapeutic aim. But the 
perfect vector covering all therapeutic and safety requirements does not exist and much 
work is needed in this important research field.
              
Endosome
Lysosome
Lipoplex
Polyplex
Adenovirus
Receptor-mediated endocytosis
or
Endocytosis
Escape from endosome
Figure 1. Schematic representation of the cellular steps of gene delivery using lipoplexes, polyplexes 
and viral vectors.
INTRODUCTION- CHAPTER 1
15
Viral Gene Delivery Systems
Viral vectors still provide the most efficient means of gene delivery. Particular viruses 
have been selected as gene delivery vehicles because of their capacity to carry foreign genes 
and their ability to efficiently deliver these genes associated with efficient gene expression. 
These are the major reasons why viral vectors derived from retroviruses, adenoviruses, 
adeno-associated viruses and herpes viruses are employed in more than 70% of the clinical 
gene therapy trials worldwide. Because these vector systems have unique advantages and 
limitations, each type of virus has specific applications for which it is best suited 33.
Novel developments of viral carrier systems mainly aim to reduce their side effects 
such as immunogenicity and cytotoxicity 34 and to improve infectivity, viral targeting, cell 
type specific expression and the duration of expression 35. One of the major obstacles in the 
use of viral vectors as therapeutic tools is the inability to control vector targeting. Different 
strategies were developed for localized delivery of viral vectors 36.
Retroviruses
Retroviruses are small RNA viruses that replicate through a DNA intermediate and 
their average diameter is ~100 nm. The retrovirus infects target cells through a specific 
interaction between the viral envelope protein and a cell surface “receptor” on the target 
cell. Retroviral vectors require mitotic cell division for transduction and can permanently 
integrate into the genome of the infected cell without expressing any immunogenic viral 
proteins. Their disadvantages include the facts that the MLV-based retroviral vectors require 
cell division for stable infection, and that their coding capacity prevents the delivery of large 
genes. The recent development of vectors based on lentiviruses (a subclass of the 
retroviruses) such as HIV 1, which can infect certain non dividing cells, should allow the in 
vivo use of retroviral vectors for gene therapeutic applications 37.
Adenviruses
Adenoviruses are non-enveloped linear double-stranded DNA viruses of ~70 nm 
diameter. 51 human AdV serotypes have been identified, grouped in six species (A–F), which 
mostly cause mild infection of the upper respiratory tract and eye infections 38. They can 
carry about 8 kb foreign DNA. Adenoviral vectors can efficiently deliver genes to a wide 
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variety of dividing and non-dividing cell types 39. Briefly, they have the ability to infect a wide 
variety of cell types, including dividing and non-dividing cells, high efficiency of gene 
transfer, no integration into the host genome, relatively large transgene capacity, easy 
manipulation and high titers. Their drawbacks include limited duration of transgene 
expression and immunogenicity in vivo 40.
Adeno-associated viruses
Adeno-associated viruses (AAV), a member of the parvovirus family, are single-
stranded DNA viruses that require a helper virus such as adenovirus or HSV for replication. 
They are icosahedral, ~20-25 nm diameter and contain a capsid protein. No pathology 
appears to be associated with infection by AAV. Wild-type AAV is able to infect non-dividing 
and dividing human cells and to stably integrate into a specific locus on chromosome 19 41,42, 
but has a limited DNA loading capacity. AAV may be highly suitable for the delivery of genes 
to specific target cells in vivo, without inducing an immune response to the infected cells 43.
Herpes simplex viruses
Herpes simplex viruses (HSV) are also being developed for gene therapy applications 
44-48. HSV is a dsDNA virus which has the advantage of being able to infect non-dividing cells, 
establishing latency in some cell types, and having the capacity to carry large regions of 
exogenous DNA 49. Although this virus can deliver large amounts of exogenous DNA, 
cytotoxicity and maintenance of transgene expression remain as obstacles. The ability to 
establish latency in neuronal cells makes HSV an attractive vector for treating neurological 
disorders such as Parkinson’s and Alzheimer’s 37.
Non-Viral Gene Delivery Systems
Although viral systems are still the most efficient vectors for gene delivery several 
problems are inherent to this system 50-53. Besides the clinically dangers of viral gene delivery 
system, several non-viral systems have been proposed. They have advantages due to their 
low immunogenicity, their capacity to deliver large genes and the fact that large scale 
production is possible at low cost 54. Therefore, there is increasing interest in the use of non-
viral delivery system, including physical and chemical approaches.
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Physical methods
Physical methods, which are carrier-free, enhance nucleic acid transfer into cells by 
employing a physical force and temporarily disrupting the cell membrane. Several physical 
methods have been investigated such as electroporation 55-59, hydrodynamic injection 60-62, 
sonoporation 63-65, or ballistic pressure (gene gun) 66,67.
Chemical methods
Chemical methods make mostly use of positively charged synthetic or natural carriesr
to deliver the nucleic acids into the target cells. This delivery system is broadly subdivided in 
polymer- and lipid-based carriers. Because of the permanent cationic charge, these carriers 
interact electrostatically with the negatively charged nucleic acids to form "polyplexes" 
(being nucleic acid/cationic polymer complexes) or "lipoplexes" (being nucleic acid/cationic 
lipid complexes), respectively. This complexation protects the nucleic acids against 
degradation by nucleases, creates a less negative surface charge, compact the size of the 
nucleic acids which promotes internalization, and can aid the intracellular trafficking of the 
nucleic acids. Many nucleic acid-carrier complexes aggregate in the presence of salt or 
serum, which mostly needs the incorporation of poly(ethylene glycol) (PEG) in the complexes 
to stabilize them 68,69. The molecular design of non-viral vectors is currently further 
advancing with the aim to overcome a multitude of barriers, both extracellular and 
intracellular, that presently limit gene transfer 70-72.
Polymer-based gene delivery 
Cationic polymers are a leading class of molecular gene delivery systems 73-78. In 
recent years, biodegradable polymers have been designed as nucleic acid delivery systems. 
Their reduced toxicity and the absence of accumulation of the polymer in the cells after 
repeated administration are the advantages of these polymers 73. Commonly used 
polycations include: poly(ethylene imine) (PEI) 79, cationic dendrimers 80 , poly-(L-lysine) (pLL) 
81, poly(ester)s and cationic polysaccharides (dextran spermine) 82 (Fig. 2). Among different 
polycations used for gene delivery, cationic polysaccharides are attractive candidates. They 
are natural, with low toxicity, biodegradable and generally biocompatible 54. Chitosan is one 
of the most reported non-viral naturally derived polymeric gene carrier from this group 83,84.
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Figure 2. Structure of some cationic polymers commonly used for nucleid acid delivery: A) linear PEI, 
B) pLL, C) poly(β-amino ester), D) cationic polysaccharides.
Liposome-based gene delivery
Cationic liposomes are spherical, nano-sized artificial vesicles, composed of cationic 
and other (helper) lipids that form one or more (phospho) lipid bilayers enclosing aqueous 
compartments 85,86. Complexation of nucleic acids to cationic liposomes results in positively 
charged lipoplexes (LPX) which facilitates the interaction with the negatively charged cell 
membrane. The cationic LPX structure is still under discussion and depends on many factors: 
an “external” model, in which the nucleic acids are adsorbed onto the surface of cationic 
liposomes, or an “internal” model, in which the nucleic acids are surrounded or “coated” by 
a lipid envelope 87. Cationic liposomes have been investigated extensively as non-viral gene 
carrier for efficient gene delivery 88-91. However, the liposomes are often toxic and 
transfection results can vary significantly between different cell lines. The commonly used 
cationic lipid N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammoniumchloride (DOTAP), the 
neutral lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), together with the 
general structure of LPXs are depicted in Figure 3.
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Therapeutic nucleic acid
Therapeutic nucleic acid Lipolex
Cationic 
liposome
DOTAP
DOPE
Figure 3. Representation of a cationic liposome, composed of DOTAP and DOPE, and the formation of 
a lipoplex
Reverse Transfection
Typically, in transfection experiments (in vitro) the nucleic acids, either in free form 
or complexed with chemical reagents, are delivered into target cells by “direct 
administration”; the nucleic acid solution/dispersion is applied on top of the cells which are 
typically cultured at the surface of wells.
Recently, immobilizing nucleic acids or viral vectors onto the surface of a culture 
substrate prior to cell seeding has been proposed. This alternative delivery system was 
termed "reverse transfection" (in case naked or complexed DNA or siRNA is used) or 
"reverse transduction" (in case viral vectors are used), because in contrast to conventional 
transfection protocols, first the DNA is “seeded” followed by addition of the cells (Fig. 4).
Reverse transfection, also termed substrate-mediated delivery or solid-phase delivery, may 
improve transfection/infection efficiency and may be especially useful in the creation of cell 
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microarrays. The immobilization of nucleic acids may improve the transfection as the nucleic 
acids are in constant and close contact with the cells. Additionally, transfection is observed
only in the location at which nucleic acids are immobilized 92.
Solid supports are being developed that optimally bind the viruses 93,94 or the non-
viral DNA complexes 95,96. Clearly, maximal transfection efficiency requires good balance 
between a sufficiently strong binding of the DNA material to the support on the one hand 
and a sufficient release of the DNA from the support into the cells on the other hand 97. 
A B
Nucleic acid up take 
from solid surface
Glass slide
Immobolize  nucleic acid
Seeding cells 
(cover the slide with cells)
Gene expression
Gene expression
Spoting  the nulcleic acids solution onto  the slide
Seeding cells
Spotting pin
Adding nucleic acids
Figure 4. Schematic illustration of in vitro cell transfection. A) Bolus addition of nucleic acids to the 
media after cell seeding. B) Reverse transfection which immobilizes nucleic acid to a solid surface 
prior to cell seeding. 
Several strategies have been developed to immobilize nucleic acids on solid surfaces. 
They can be immobilized through specific or non-specific interactions or even by 
multilayered assemblies. Specific interactions can be introduced through complementary 
functional groups on the vector and surface, such as antigen–antibody or biotin–avidin. 
Segura et al. have shown that PLL and PEI, modified with biotin residues could complex with 
DNA and bind to a neutravidin substrate 95,96. Transfection was maximal when complexes 
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contained biotin residues attached to a small fraction of the cationic polymers 96 and it was 
observed only at the location where complexes were bound.
In non-specific interaction, non-covalent mechanisms 98-102, including hydrophobic, 
electrostatic, and van der Waals interactions are involved. Bielinska et al. 98 were the first to 
report the use of solid support membranes for DNA delivery mediated by dendrimer based 
nucleic acid complexes which were non-specifically bound to the support. Ziauddin and 
Sabatini further developed this challenge by miniaturizing and parallelizing the reverse 
transfection of cells 103.
A better understanding of the physicochemical properties of the nucleic acid complexes and 
the substrates may improve the extent of transgene expression and cell viability in reverse 
tranefection setups 101. Delehanty et al. 104 quantified the transfection efficiency of 
mammalian cells on different microscope slide substrates. They found that the size and 
concentration of the pDNA spots on the slides were dependent on the hydrophobicity of the 
substrate.
Uchimura et al. reported a different method to improve the efficiency of reverse 
transfection. They proposed to conjugate gold nanoparticles to the DNA/reagent complex 
which can regulate the size and the density of the complex printed on the solid surface 108. 
They also found that an antibody-coated surface allows the most effective delivery of genes 
by reverse transfection 106.
Multilayered polyelectrolyte films are another possibility to immobilize nucleic acids 
on solid surfaces. Polyelectrolyte multilayers (PEM) can be/are generated by sequential 
adsorption of oppositely charged polymers (i.e. polyelectrolytes; so called layer-by-layer 
(LbL) adsorption) on a charged planar substrate 107. Figure 5 is a schematic illustration of the 
LbL process. A charged surface (being a flat surface or the surface of e.g. a microcarrier), is 
immersed into an aqueous solution of an oppositely charged polyelectrolyte. After a certain 
adsorption time (15 min) the substrate is removed and washed with water in order to 
remove the excess of polyelectrolyte. In the next step the substrate is immersed into the 
second polyelectrolyte solution which has a charge opposite to the first polyelectrolyte. This 
second polyelectrolyte adsorbs onto the layer of the first polyelectrolyte which reverses the 
surface charge. Again a washing step is performed and the whole procedure can be repeated 
as many times as one desires. In this way one can easily prepare multilayered films with 
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tunable physicochemical properties as both the number of layers as well as their 
composition can easily be varied.
Layer-by-Layer coating technique has become a new and general way to modify and 
functionalize surfaces and provided the opportunity to develop platforms for delivery of
biological materials such as proteins and drugs to the cells 108-114. Recently, different studies 
have demonstrated the efficient release of pDNA from multilayered assemblies made of 
naked pDNA and a degradable polyamine 102,115, or from pre-complexed DNA, with PEI, into 
multilayer architectures made of neutral degradable and synthetic polyelectrolytes 116,117.
Jessel et al have shown that gene delivery can be enhanced from multilayers by the presence 
of charged cyclodextrins 118,119. 
In general, glass and plastics are used as solid surface in reverse transfection but 
other materials, such as metals, could contribute to the development of this approach. Many 
research groups have reported on the developments of stents, which permit gene delivery 
to endothelial cells by reverse transfection. In these studies, plasmid and adenovirus vectors 
are loaded onto the stent surface together with various polymers 120-121. Yamauchi et al 122
made use of an LbL process to deposit cationic lipids and plasmid DNA on gold surfaces to 
efficiently transfer pDNA to cells. Lynn et al. reported on the fabrication of ultra thin 
polyelectrolyte films that permit immobilization and controlled release of pDNA from the 
surfaces of stainless steel intravascular stents 123.
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Figure 5. (A) Schematic representation of the deposition of a polyelectrolyte film on a slide. Steps 1 
and 3 represent the adsorption of respectively a polycation and polyanion, steps 2 and 4 are washing 
steps. (B) Simplified molecular picture of the first two adsorption steps, depicting film deposition 
starting with a negatively charged substrate. (C) Schematic illustration showing the preparation of 
LbL coated microcarrier(D) Chemical structure of poly(styrene sulfonate) (PSS) (right) and 
poly(allylamine hydrochloride) (PAH) (left), often used polyions to build LbL films.
Multiplex Assay Technologies
The desire for screening more compounds against a large numbers of targets, for 
both research and diagnosis applications, has led to multiplex technologies. 
A monoplex assay aim to analyse a single compound in e.g. a biological sample while 
multiplex assays aim to carry out multiple analysis simultaneously in the same sample. 
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Multiplex assays aim to save both time and reagents by parallelized and miniaturized 
analysis.
A main challenge in multiplexing technologies is to be able to identify quickly and 
accurately each reaction. There are two main strategies for doing this, resulting in positional 
and non-positional arrays 124-127. One strategy relies on the exact location (x,y coordinate) of 
the molecules on the solid surface (microtiter plate or microarray) as illustrated in Figure 6A. 
This method of identification is known as positional encoding. In a second strategy (Fig. 6B), 
the molecules are bound to microcarriers and the reaction is carried out on their surface, 
therefore the identification is possible by the code on microcarriers. 
Figure 6. (A) In a positional array (flat surface array) the identity of each probe (being a nucleic acid, a 
protein or a cell) is known from its location on the array. (B) In a non- positional array (a suspension 
array) each probe at the surface of the microcarrier is identified by the code written in the 
microcarrier. 
Microarrays
Over the last years, microarray technology has evolved as a propitious platform for 
the multiplex analysis 128-130. This technology is a powerful method for life science 
researchers and is also beginning to be used in diagnostic and treatment application 131-133. 
Microarrays consist of immobilized biomolecules (nucleic acids, proteins) on a planer or non-
planer surface. The immobilized biomolecules (a) must retain their activity, (2) must remain 
stable, and (3) may not desorb during reaction or washing steps 134. Several materials could 
be used as solid surface for microarrays such as glass and plastics. Though microarray 
technology was initially developed for DNA mapping 135 and sequencing by hybridization 136-
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139 and also as a tool for transcript-level analyses 140, it could be adapted for the analysis of
other molecular entities, such as proteins 141-144, tissue samples and even living cells 145-147. In 
fact this technology has meanwhile spread into many areas and became a device for diverse 
purposes 148-149.
Positional microarrays
In a positional or planer array (Fig. 6A), which is a common format to perform 
multiplexed assays, molecules such as antibodies or nucleic acids, are immobilized on a two-
dimensional grid. The identification of each molecule relies on its position in the grid. 
The main advantage of positional arrays is that they allow thousands of individual 
tests to be performed in parallel but they have also some limitations 150. Positional arrays are 
often inflexible because they impose a predetermined panel of tests on the user. The rate of 
binding on positional arrays and also their sensitivity are important limiting factors. 
Positional arrays have had major impact on high throughput screenings, but because of their 
limitations recently the possibility of using suspension arrays (see below) has emerged as an 
alternative. 
Non positional microarrays
Recently, non-positional microarrays (Fig. 6B), also known as suspension arrays, have 
proven to be a very promising alternative to positional arrays due to their inherent and 
unique characteristics, such as a higher flexibility in array implementation and no 
requirement for a sophisticated high-precision spotting device 151. The use of microspheres 
also can facilitate the separation and washing steps and they are inexpensive to produce in 
large number 150. 
In this technique, each of the microcarriers needs to be encoded to allow the 
identification of molecule bound to its surface. This method allows uniquely encoded 
microcarriers to be mixed and subjected to an assay simultaneously 152.
Meanwhile a large number of techniques for the encoding of microparticles have
been reported: spectrometric 153-157, graphical 158-163, electronic 164-165 and physical 166-
167.Recently, our group introduced a way for encoding microcarriers (being fluorescent 
polystyrene microspheres) that holds much promise for use in biomedical research and 
diagnostics. These microspheres, called Memobeads, were encoded by spatial selective 
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photobleaching. As shown in Figure 7 they can carry a digital code (like a dotcode or a 
barcode) in their middle plane. This technique provides a virtually unlimited number of 
unique codes, hence overcoming the (sometimes) limitations of other encoding strategies
162.
                
Figure 7. A 40 µm diameter fluorescent microsphere with a bleached barcode and alphanumeric 
code.
Our group showed recently that a LbL coating, composed of polyanions (like polystyrene 
sulfonate; PSS), polycations (like polyallyamine hydrochloride; PAH) and ferromagnetic 
chromium dioxide nanoparticles (CrO2 NP), can be easily applied (Fig. 8) 168. The CrO2 NP
allows an optimal positioning of the Memobeads in a magnetic field, which is necessary to 
read the code at the time of decoding (Fig 8). On top the LbL coating is ideally suitable for 
binding probes (like antibodies, nucleic acids) at the surface of the beads.
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Figure 8. Schematic illustration showing LbL coating of green fluorescent polystyrene microspheres. 
The polycation PAH and the polyanion PSS are alternately adsorbed to the surface of the 
microcarrier. Magnetic CrO2 nanoparticles are immobilized in the LbL coating 168.
Cell microarrays
In cell microarrays cells are grown respectively on the flat surface of a positional 
array or on the surface of encoded carriers in non positional arrays. Cell microarrays, in 
which the cells are analyzed for various types of responses, show many advantages as they 
allow using very small volumes of expensive reagents and small number of rare cells. The 
applications of cell microarrays could be very diverse. Though, challenges/limitations such as 
cell destruction, low efficiency of transfection, difficulties in detecting signals in the cells 
currently remain. The most obvious application for cell microarrays is the biological
screening of compounds. An even more promising avenue would be the analysis of gene 
expression and/or gene knock down due to the uptake of compounds (or plasmid DNA or 
siRNA) by cells. 
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Cell microarray can be divided into two main categories depending on whether cells 
themselves are microarrayed (genuine cell arrays) or cells are bound to microarrayed 
biomolecules (substrate based cell array)
Genuine cell microarrays
The different types of cells are arrayed on a flat surface (and thus identified by the 
array coordinates; positional array) or on encoded carriers, and are probed with one or 
multiple reagents like e.g. antibodies or pharmaceutical compounds. 
In a positional cell array, immobilization of cells into a precise position is challenging. 
One way to generate cell microarrays is by miniaturizing microliter plates: plates containing 
96 wells (with a volume between 100 nl and 1 µl) which are addressable by a piezonozzle
have been developed 169. Stephan et al. developed an array containing several types of 
frozen cells that can be labelled with specific reagents, including antibodies, DNA or RNA 
probes.170. Another way to generate a cell array is by printing cells on a glass slide. Such 
slides are covered with cell-repulsive tri-ethoxy amino propylsilane (which inhibits adhesion 
of cells to the slide) except at certain spots. This results in a matrix of circular spots on which 
cells are growing 171,172. 
Ink-jet printers have been adapted to print cells without major loss in viability 173. It is 
also possible to print fixed cells using a pin ring arrayer, in which cells are captured within 
the ring and pushed onto the surface by the pin 174. The force of dielectrophoresis (DEP) is 
another way to pattern cells in a microarray. As cells are polarizable bodies, when they flow 
over an array of electrodes they trap above the electrode 175,176.
However, direct cell arraying remains particularly challenging because most devices 
used for this purpose (such as piezonozzle and ink-jet devices) can have a deleterious effect
on cells. Although cells can stay alive, it is possible that their physiology is affected by the 
arraying process. So far, this issue has not been extensively evaluated.
As explained above, in a non positional cell array cells are identified based on codes 
in the carriers. The nature of this code can be diverse but so far only two types of coding 
approaches have been demonstrated for carriers loaded with cells. The first technology 
describes a platform in which cells grow on small cards that can be manufactured with 
different materials, which are encoded colored bars. The array is decoded by imaging with 
an automated microscope and appropriate software. Using this system, up to nine cell lines 
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have been assayed in parallel 177. Another technology uses nanometer-sized semiconductor 
crystals, quantum dots, which are incorporated into the cells (without affecting cell 
physiology) to encode the cells 178,179. Matteakis et al. showed that different sizes of 
quantum dots emit their fluorescence at different wavelengths when excited by light. They 
were able to generate up to 1023 codes with combinations of five colours 180. Such 
nanocrystals can be internalized by different cell types and the resulting encoded cells are 
analyzed by optical methods. Tagging of cells by the quantum dot-coding method can be 
applied to both adherent and suspension cells.
Substrate cell microarrays
For this type of array cells are seeded on biomaterials microarrayed on solid surface. 
Different substrates such as polymers, carbohydrates, antibodies, proteins, pDNA or siRNA 
are arrayed and interact with the attached cells. Therefore this technology allows 
exploration into the effects of a large variety of biomolecules on cell behaviour. They are 
promising tools for the large scale screening of such substrates. Here we further focused on 
transfected cell microarray technique which considered a substrate-cell microarray.
Transfected cell microarrays
Recently, several reports have suggested new screening approaches in which living-
cell microarrays are used for reverse transfection with plasmid DNA or siRNA; such 
technologies should allow the simultaneous high throughput analysis of the function of 
many different genes in many different cell types 103, 181-184. These new tools appear to be 
very promising for the rapid identification of protein function 185,186. 
Sabatini et al. were pioneering reverse transfection of cells grown on glass slides 103. 
One nanoliter of pDNA in an aqueous gelatin solution was printed at a number of locations 
on a glass slide, using a robotic arrayer. After drying, the DNA spots were exposed to a lipid 
transfection reagent and subsequently the slide was placed in a culture dish to become 
covered with adherent mammalian cells. Cells growing on the printed areas took up the 
DNA, creating spots of transfected cells. Figure 8 shows an example of the microarrays that 
can be created with this approach. 
The employment of siRNA to knockdown expression of selected genes by Mousses et 
al. significantly extended the use of transfected microarray 187.
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Figure 9. Schematic illustration of the procedure used to obtain a cell microarray by reverse 
transfection 110. The array consists of cell clusters expressing green fluorescent protein, each cluster 
about 120 µm in diameter and containing about 50-80 transfected cells.
Later, Sabatini et al. also described lentivirus-infected cell microarrays for high-
throughput screenings 188. Carbone et al. 189 have presented a cell microarray for phenotype 
screening on primary cells and cancer cells based on the reverse transduction of the cells by 
retroviruses. In this work the viral vectors were immobilized on a glass slide coated with a 
titanium dioxide layer, cells were subsequently plated on the slide in the absence of 
reagents such as lipofectamine and polycations.
It has been recently demonstrated how transfected cell microarrays can be 
successfully used in drug discovery 190. However, despite several attempts to improve this 
technology, it remains a challenge to obtain transfected cell microarrays for screening. 
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ABSTRACT
In this study the physicochemical and transfection properties of cationic 
hydroxyethylcellulose/plasmid DNA (pDNA) nanoparticles were investigated and compared 
with the properties of DNA nanoparticles based on poly(ethylene imine) (PEI) which is widely 
investigated as gene carrier. The two types of cationic hydroxyethylcelluloses studied, 
polyquarternium-4 (PQ-4) and polyquarternium-10 (PQ-10), are already commonly used in 
cosmetic and in topical drug delivery devices. Both PQ-4 and PQ-10 spontaneously interact 
with pDNA with the formation of nanoparticles of approximately 200 nm in size. 
Gelelectrophoresis and fluorescence dequenching experiments indicated stronger 
interactions between pDNA and the cationic celluloses than between pDNA and PEI. The 
cationic cellulose/pDNA nanoparticles transfected cells to a much lesser extent than the PEI 
based pDNA nanoparticles. The low transfection property of the PQ-4 /pDNA nanoparticles 
was attributed to their neutrally charged surface which does not allow an optimal binding of 
PQ-4/pDNA nanoparticles to cellular membranes. Although the PQ-10/pDNA nanoparticles 
were positively charged, and thus expected to be taken up by cells, they were also much less 
efficient in transfecting cells than PEI/pDNA nanoparticles. Agents known to enhance the 
endosomal escape were not able to improve the transfection properties of PQ-10/pDNA
nanoparticles indicating that a poor endosomal escape is, highly likely, not the major reason 
for the low transfection activity of PQ-10/pDNA nanoparticles. We hypothesized that the 
strong binding of pDNA to PQ-10 prohibits the release of pDNA from PQ-10 once the PQ-
10/pDNA nanoparticles arrive in the cytosol of the cells. Tailoring of the nature and extent of 
cationic side chains on this type of cationic hydroxyethylcellulose may be promising to 
further enhance their DNA delivery properties.
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Chapter 2
Physicochemical and Transfection 
Properties of Cationic 
Hydroxycellulose/DNA Nanoparticles
INTRODUCTION
The major progress in the field of genomics has encouraged numerous scientists to 
work on suitable carriers for delivering genes to target cells. Indeed, the biological efficacy 
(i.e. the production of a certain protein) of administered “naked” DNA is restrained as it 
cannot efficiently overcome cellular barriers on its way to the nucleus. E.g. the cellular 
uptake of naked DNA is poor due to its large size, hydrophilicity, and negatively charged 
backbone. In addition, naked DNA is very susceptible to degradation by nucleases in the 
extracellular matrix and in the cells. Consequently, efficient intracellular delivery of DNA is 
highly dependent on suitable carriers which protect the DNA against degradation, allow the 
DNA to cross cellular membranes and to escape from endosomes, and guide the DNA into 
the nuclei of the cells.
Worldwide many laboratories are searching for appropriate pharmaceutical carriers 
for DNA. Different types of cationic lipids and cationic polymers are under investigation as 
non-viral DNA carriers 1,2. Cationic lipids, as well as cationic polymers, spontaneously form 
interpolyelectrolyte complexes with negatively charged nucleic acids, called respectively 
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lipoplexes and polyplexes. The physicochemical features that govern the biological activity of 
lipo- and polyplexes are, however, not well understood, partly due to the complexity of the 
association and dissociation behavior of such complexes. 
Cationic polysaccharides (like e.g. cationic dextrans, cationic celluloses, cationic guar, 
chitosan) are, for various reasons, widely used in both cosmetics and topical drug delivery 
systems3. Recently, cationic polysaccharides were also investigated for DNA delivery 
purposes. In particular, Azzam et al.4 tested over 300 different types of cationic 
polysaccharides for gene transfection, starting from various polysaccharides (of various 
molecular weight) and oligoamines. Although most of the cationic polysaccharides formed 
stable complexes with various plasmids, only certain types of the dextran-spermine based 
polyplexes transfected cells in vitro 4,5.
A major obstacle for in vivo gene delivery is the interaction of the DNA complexes with 
(extra) cellular fluids 6,7,8. Indeed, binding of (extra)cellular proteins can induce aggregation, 
(partial) dissociation and opsonization of the charged DNA-complexes. It is well known that 
pharmaceutical carriers bearing neutral, hydrophilic segments (such as poly(ethylene glycol)
(PEG)) at their surface are attractive to avoid opsonization. Pegylated derivatives of dextran-
spermine were reported to give efficient transfection in serum rich media and to induce 
gene expression in the liver of mice after IV administration9. Transfection efficiency could be 
also increased by grafting fatty acids on the dextran-spermine polymers. It was believed that 
hereby the surface of the particles becomes more hydrophobic which would favour the 
hydrophobic interactions with the cell membranes 10. Cationic polysaccharides containing 
quaternary ammonium oligoamines were developed to make DNA particles with a highly 
positive surface which would promote binding of the particles to the negatively charged cell 
membranes and would thus improve cellular uptake. However, quaternary ammonium 
polysaccharides as synthesized by Yudovin-Farber et al. were less efficient in gene transfer 
than dextran-spermine based carriers 11.
A first aim of this study is to evaluate the DNA complexation properties of two types of 
cationic hydroxyethylcellulose. Polyquaternium-4 cellulose (PQ-4; Fig. 1) and 
polyquaternium-10 cellulose (PQ-10; Fig. 1) were previously characterized 3,12 ,and already 
have applications in cosmetics and topic drug delivery devices 13. In both PQ-4 and PQ-10 the 
sugar monomers are substituted with PEG. However, in PQ-4 the quaternary ammonium 
groups are directly attached to the cellulose backbone, while in PQ-10 the quaternary 
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ammonium groups are present at the end of the PEG chains 14. Also, as Table 1 shows, 
compared to PQ-10, PQ-4 is less substituted with ammonium groups. The second aim of this 
study is to investigate whether quaternized cationic celluloses are suitable for gene delivery. 
The transfection properties of quaternized cationic cellulose/DNA nanoparticles were 
compared with the transfection properties of DNA nanoparticles based on respectively 
branched and linear poly(ethylene imine) (PEI) which are widely investigated cationic 
polymers for DNA delivery purposes.
Table 1
Polymer MW (kDa) [η]dl/g XPEG n XN
PQ-4 1400 14.59 1.33 1.04 0.24
PQ-10 1700 70.09 0.51 1.52 0.51
Table 1. Molecular weight (MW), intrinsic viscosity in water at 25°C ([η]), the number of PEG-chains 
per glucose residue (XPEG), the average number of repeating units of the hydroxyethyl chains (n) and 
the number of nitrogen atoms per glucose residue (XN) of the cationic celluloses.
Figure1. Schematic molecular structures of PQ-4 and PQ-10.
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MATERIALS & METHODS
Materials
PQ-4 (Celquat H-100) and PQ-10 (Celquat SC-230M) were obtained from National 
Starch and Chemical Ltd. The physicochemical properties of PQ-4 and PQ-10 as provided by 
the supplier are shown in Table 1. Branched poly(ethylene imine) (BPEI, MW 25 KDa) was 
purchased from Sigma. Linear poly(ethylene imine) (LPEI, MW 22 KDa) was a kind gift from 
Professor Ernst Wagner (Ludwig Maximilian University, Munich, Germany). Secretory 
alkaline phosphatase (SEAP) plasmid DNA (pMet7-hβc-SEAP) was a kind gift from Professor 
Tavernier (Ghent University, Belgium). pMet7-hβc-SEAP was amplified in Escherichia Coli and 
purified by the Qiagen Plasmid Mega Kit. The plasmid DNA was fluorescently labeled using
the Mirus Label IT Nucleic Acid Labeling Kit (Panvera Corporation, USA). Picogreen was 
purchased from Molecular Probes. Poly-L-aspartic acid (pAsp), dextran sulfate (DS), 
chloroquine and ethidium bromide were purchased from Sigma. The cellulase used in this 
study was the FIP (Féderation Internationale Pharmaceutique) standard (0.147U/mg). The 
fusogenic peptide INF-7, a 24 amino acid containing peptide with fusogenic activity derived 
from the influenza virus, was a kind gift from Professor Hennink (Utrecht University, The 
Netherlands). 
Preparation of Polyplexes
Stock solutions of the cationic polymers (PQ-4(3.0 mg/ml), PQ-10(3.0 mg/ml), BPEI 
(12.98 mg/ml) and LPEI (7.6 mg/ml)) were diluted in 20mM HEPES buffer at pH 7.4. In 
general polyplexes (varying in N/P ratio, see below) were prepared by adding (in one step) 
different volumes of the polymer stock solution (depending on ratio) to a fixed amount (1µg) 
of the DNA stock solution (1mg/ml in HEPES buffer) and adding HEPES buffer to reach final 
volume, 40 µl. The mixture was vortexed for 10 sec and the polyplexes were allowed to 
equilibrate for 30 min at room temperature prior to use. 
In this study the N/P ratio is the ratio of the number of nitrogen atoms on the 
cationic cellulose to the number of phosphor atoms on the DNA. It was assumed that 1 µg of 
DNA contains 3.43 nmol phosphor and that 1 µg of PQ-4, PQ-10 and PEI contains 
respectively 2.0 nmol, 3.2 nmol and 23.3 nmol nitrogen. Polyplex were also prepared from 
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‘low molecular weight PQ-10’. The low molecular weight PQ-10 was obtained by incubating 
PQ-10 solutions (3 mg/ml in 20mM HEPES buffer at pH 7.4) with cellulase at 37°C. The 
reaction was terminated by heating the sample for 10 min at 95°C. 
Particle Size and Zeta Potential Measurements on the Polyplexes
Dynamic light scattering measurements (DLS) on the polyplexes were carried out on a 
Malvern 4700 instrument at 25°C and at an angle of 90 degrees. The incident beam was a 
HeNe laser beam (633 nm). To avoid dust particles, the HEPES buffer used in the preparation 
of the polyplexes was filtered through a 0.45 µm membrane (Schleicher & Schuell). 
Polystyrene nanospheres (220 ± 6 nm; Duke Scientific) were used to verify the performance 
of the instrument. The particle size of each polyplex sample was measured three times.
Zeta potential measurements on the polyplexes were performed by electrophoretic 
light scattering at 25 °C on a Malvern Zetasizer 2000. Polystyrene nanospheres (-50 mV; 
Duke Scientific) were used to verify the performance of the instrument. The zeta potential of 
each polyplex sample was measured three times.
Gelelectrophoresis on the Polyplexes
Agarose gelelectrophoresis experiments were performed to monitor the 
complexation of pDNA to the cationic polymers. The slots of the agarose gel (1% agarose in 
Tris-borate EDTA buffer) were loaded with 40 µl of sample. Electrophoresis was carried out 
at 100 V for 60 min. The bands containing pDNA were visualized by staining the gels with an 
ethidium bromide solution for 30 min at room temperature, followed by UV illumination. 
Fluorescence Measurements on the Polyplexes in the Presence of Picogreen
The complexation of pDNA to the cationic polymers was further investigated by 
measuring the extent of the quenching of picogreen. Picogreen is only fluorescent when it 
can intercalate with pDNA, thus when free (uncomplexed) pDNA is present. Briefly, 1µg of 
pDNA was mixed with increasing amounts of cationic polymer in HEPES buffer (at pH 7.4) 
and incubated for 30 min at room temperature to equilibrate. The fluorescence of the 
polyplex dispersions was measured 10 min after adding the picogreen to the dispersions. A 
SLM-Aminco Bowman spectrofluorimeter was used (λex 480 nm, λem 520 nm). 
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Cell Viability and Cell Transfection Measurements
For evaluating the cytotoxicity and transfection properties of the polyplexes COS-7 
cells were cultured in DMEM (Dulbecco’s modified eagle medium) containing glutamine 
(Gibco) supplemented with 10% FBS (fetal bovine serum) (Gibco) and antibiotics (100 
units/ml penicillin and 100 μg/ml streptomycin, Sigma). The cells were seeded in 24-well 
culture plates at a density of about 25 000 cells/cm2. After 24-48h incubation at 37°C in 
humidified air containing 5% CO2, the cells were rinsed with PBS (phosphate buffer saline). 
Subsequently 500µl of culture medium (without serum), containing 40µl polyplexes, was 
added to each well and incubated at 37°C in a humidified air (5% CO2) atmosphere for 2h. 
Subsequently, the transfection medium was removed, 500 µl DMEM (containing 10% FBS) 
was added to each well. Two days later, SEAP activity was determined in the medium using 
4-MUP (4-methylumbellifery phosphate) 15. Then the fluorescence due to conversion of 4-
MUP to 4-methylumbelliferone was measured with a Wallac Victor 2 plate reader (Perkin 
Elmer; λex 360 nm, λem 449 nm). To take into account the number of cells per well, the 
measured SEAP activity was normalized; therefore we divided the SEAP activity by the total
protein content in the corresponding well which was measured using the DC protein assay 
(BioRad). The cytotoxicity of the polyplexes was measured by the EZ4U assay (Lucron 
Bioproducts; Biomedica). COS-7 cells were seeded in 96-well culture plates at a density of 
about 7000 cells/well. The cells were incubated with polyplexes at different ratio. 
Consequently the polyplex dispersions were removed from the cells in the wells. To each 
well 20µL EZ4U substrate in 200µl culture medium was added and incubated with the cells 
for 2-5 h. The absorbance of each well was measured with a Wallac Victor 2 plate reader 
(Perkin Elmer; λex 450 nm, λem 495).
Dissociation of the Polyplexes
To study the dissociation of the polyplexes by polyanions, an excess of dextran 
sulfate (DS) or poly-L-aspartic acid (p(Asp)) was added to the polyplex dispersions (at a ratio 
of respectively 40:1 for DS/pDNA and 10:1 for p(Asp)/pDNA). The resulting mixtures were 
incubated for 30 min at room temperature. Gelelectrophoresis and the picogreen
fluorescence assay (see above) were used to determine the extent of dissociation of the 
polyplexes.
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Confocal Laser Scanning Microscopy (CLSM)
CSLM (MRC1024 Bio-Rad) was performed on COS-7 cells which were transfected by 
polyplexes containing fluorescently labeled pDNA (see below). The transfection of the cells 
with polyplexes occurred as described above. The cells were seeded in a glass culture dish to 
allow optical imaging. 
Plasmid DNA Labeling
The plasmid DNA labelling reagents were obtained from Mirus Corporation. DNA 
(pMet7 hc SEAP) was modified using Label IT reagents according to the recommendations 
of the manufacturer. Briefly, Label IT reagent was added to a DNA solution (100 µg DNA/ml 
(20 mM) HEPES buffer at pH 7.4) at 1:1 ratio (weight label/weight DNA) and incubated at 
37°C for 1 h. To remove unbound fluorescein the pDNA was precipitated by adding 0.1 
volumes of 5M NaCl and 2 volume of ice cold 100% ethanol to the pDNA. After 
centrifugation, the pellet was washed with 70% ethanol until the supernatant contained no 
fluorescein. Consequently the pellet was dissolved in HEPES buffer and the concentration 
was determined by absorption at 260 nm.
RESULTS & DISCUSSION
pDNA Binds to Cationic Cellulose
As outlined above, the binding of pDNA to the cationic polymers was studied by 
gelelectrophoresis. The gelelectrophoresis measurements in Figure 2 clearly show that at 
N/P ratios of 1 and higher both the cationic celluloses and poly(ethylene imine)s bind all the 
pDNA. The polymer/pDNA complexes remain in the slots as they are unable to migrate 
through the gel. Clearly, a difference between PQ-4 and PQ-10 is that at N/P ratio 0.1 PQ-4 
binds all the pDNA whereas PQ-10 binds only a part of the pDNA.
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Figure 2. Gelelectrophoresis on dispersions of (A) PQ-4/pDNA and PQ-10/pDNA complexes and (B) 
BPEI/pDNA and LPEI/pDNA complexes. The N/P ratio was varied.  
 
Figure 3 shows the complexation between the cationic celluloses and pDNA as 
revealed from the fluorescence quenching assay. As explained in the materials and method 
section, picrogreen was added to the dispersions to detect free pDNA. As expected, the 
fluorescence decreases at higher concentrations of the cationic polymers: it indicates that 
the pDNA molecules not only bind to the cationic polymer chains but that pDNA molecules 
also condense to such an extent that picrogreen has less access to/ less intercalates in the 
double stranded DNA yielding less fluorescence. In case of PQ-4, LPEI and BPEI the 
fluorescence is almost completely disappeared at an N/P higher than 1. This confirms the 
gelelectrophoresis data in Figure 2 as free pDNA was not detected in the dispersions. In case 
of PQ-10, however, even at higher N/P ratio’s the fluorescence seemed to be only partially 
quenched when compared to the fluorescence of the corresponding free pDNA solution. 
Although, the gelelectrophoresis data showed that at these N/P ratios PQ-10 binds all the 
pDNA. The partial quenching in Figure 3 probably indicates that PQ-10 does not condense 
pDNA as tightly as the other cationic polymers, still allowing picrogreen to intercalate to a 
certain extent in the pDNA. 
PHYSICOCHEMICAL AND TRANSFECTION PROPERTIES OF CATIONIC HYDROXYCELLULOSE/DNA NANOPARTICLES- CHAPTER 2
53
0
0,2
0,4
0,6
0,8
1
1,2
0 1 5 10 15 20
Re
la
tiv
e 
flu
or
es
ce
nc
e
N/P ratio
PQ-4
PQ-10
BPEI
LPEI
Figure 3. Relative fluorescence of cationic cellulose/pDNA and PEI/pDNA dispersions (as a function of 
the N/P ratio of the complexes) containing picogreen. The amount of pDNA was kept constant (1µg) 
and the concentration of cationic polymers was increased. The fluorescence of a (free) pDNA solution 
was set to 1. The fluorescence of three samples was measured. The error bars were smaller than the 
size of the symbol.
Size and Zeta Potential of pDNA /Cationic Cellulose Complexes
Figure 4A shows that at N/P ratio of 1 the cationic cellulose/pDNA complexes are 
substantially larger than the PEI/pDNA complexes; at higher N/P ratio’s all types of pDNA 
complexes are of similar size (between 150 and 300 nm). Figure 4B reveals that at high N/P 
ratio’s the PQ-10 based complexes are clearly positively charged while the zeta-potential of 
the PQ-4 based complexes is significantly lower. This can be explained by the structural 
differences between PQ-4 and PQ-10 (Fig. 1). The sugar backbone of PQ-4 is substituted with 
both polycation chains (which bind the DNA) as well as with neutrally charged PEG chains 
(which are not involved in the binding of pDNA). We assume that the PEG chains form a 
neutral shell around the inner core of the polyelectrolyte complexes. The resulting 
complexes might resemble the core-shell polyplexes formed between graft-polyelectrolytes 
and oppositely charged polymers or biomacromolecules16. In contrast, in PQ-10 the cationic 
groups are attached to the free end of the PEG side chains. Therefore we assume that, upon 
binding the pDNA, the PEG strands are (sterically) not allowed to create a neutralizing PEG-
shell around the complexes.
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Figure 4. Hydrodynamic diameter (A) and zeta potential (B) of cationic cellulose and PEI based pDNA 
nanoparticles. Data represent the mean values obtained on 5 (independently prepared) samples. 
Cytotoxicity of pDNA/Cationic Cellulose Complexes
As outlined in the introduction, we are interested in how cationic cellulose based 
DNA nanoparticles behave in a cellular environment. Clearly, an absolute requirement is that 
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the nanoparticles should be not toxic for cells. Therefore the cytotoxicity of the cellulose 
based polyplexes was studied using COS-7 cells. Figure 5 shows the results of the cell viability 
assay. PQ-4 and PQ-10 based pDNA complexes show low toxicity as more than 90% of the 
cells remains alive. At higher N/P ratio the cationic cellulose/ pDNA dispersions seemed to 
be slightly more toxic which may be due to the presence of a higher amount of (free) 
cationic cellulose damaging the cellular membranes 17. The PEI based complexes 
demonstrated low cytotoxicity as well. Indeed, COS-7 cells seemed to tolerate well the PEI 
based complexes used in this study as the cell viability was around 80% compared to 
untreated cells. Although it has been reported that low molecular weight PEI shows low 
membrane damaging 18 and that cell damaging is more severe for free PEI compared to 
PEI/DNA complexes 19, this low cytotoxity of the PEI polyplexes was rather unexpected as 
some studies reported significant cytotoxicity 20,21
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Figure 5. Viability of COS-7 cells after incubation with cationic cellulose and PEI based pDNA 
nanoparticles. The data are the mean values obtained on three (independently prepared) samples.
Also, the group of Kissel 22,23 showed that the molecular weight and type of PEI 
influences the cytotoxicity. From MTT-assay’s [3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] they concluded that cytotoxicity of PEI is affected by polymer size and 
structure: high cationic charge densities, compact and highly branched structures, and high 
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molecular weights render PEI less biocompatible 18. Anyhow, the fact that the cationic 
cellulose based polyplexes seemed to be well tolerated by cells was encouraging for further 
transfection experiments. 
In Vitro Transfection of Cells by pDNA/Cationic Cellulose Complexes 
Figure 6A shows the transfection efficiency of cationic cellulose and PEI based 
polyplexes in COS-7 cells as a function of the amount of pDNA per well. Note that the N/P 
ratio of all the complexes studied in Figure 6 equalled 10. Clearly, PEI based polyplexes 
transfect significantly better than cationic cellulose/pDNA complexes. LPEI proofs to be a 
better transfectant than BPEI, in agreement with earlier findings 24,25. PQ-10/pDNA 
complexes show minor transfection efficiency while PQ-4 does not transfect the COS-7 cells 
at all. As there is evidence that a positive surface charge promotes cellular uptake due to 
binding of the complexes to the negatively charged cell membranes, we hypothesize that 
PQ-4/pDNA-complexes do not transfect due to their neutral surface charge (Fig. 4B). Indeed, 
confocal microscopy measurements did not evidence any binding or uptake of the PQ-
4/pDNA nanoparticles (data not shown). We observed the same trend in transfection 
behaviour when we used Hela cells in stead of COS-7 cells (Fig. 6). 
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Figure 6. Transfection efficiency of cationic cellulose and PEI based pDNA nanoparticles in COS-7 cells 
and Hela cells as a function of the concentration of pDNA per well (n = 6). The N/P ratio of all the 
complexes equalled 10. (note: COS cells 0.5µg/well for LPEI/pDNA: not determined)
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These results lead to the intriguing question why the positively charged PQ-10/pDNA
complexes fail in transfecting COS-7 and Hela cells efficiently, while PEI/pDNA complexes of 
similar surface charge successfully deliver the same pDNA in the cells. The molecular weight
of PQ-10 is 1700 kDa while the molecular weight of respectively LPEI and BPEI is 22 kDa and 
25 kDa. To find out whether a lower molecular weight of PQ-10 would improve the 
transfection efficiency we degraded the sugar backbone of PQ-10 by treating it with
endocellulase prior to complexation with pDNA. Capillar viscosity measurements on PQ-10 
solutions incubated with cellulase showed a significant decrease (65%) in viscosity indicating 
that that PQ-10 indeed degraded. Figure 7 shows the transfection efficiency of the 
pretreated PQ-10: compared to high molecular weight PQ-10, lower molecular weight PQ-10 
transfects better, however, still less efficient than BPEI.
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Figure 7. Transfection efficiency of cationic cellulose and PEI based pDNA nanoparticles in COS-7 
cells. DPQ-10 denotes the complexes made from degraded PQ-10. The N/P ratio of the complexes is 
10. The data are the mean values obtained on three (independently) prepared samples.
It has been proposed in many studies that the good transfection properties of PEI are 
partly due to the fact that it facilitates the escape of pDNA from the endosomes. This is 
usually explained by the fact that in the endosomes PEI works as a buffer (“proton-sponge”) 
based on the uniqueness of its chemical structure 26 which eventually causes swelling and 
disruption of the endosomes. Consequently, PEI polyplexes in the endosomes can be 
efficiently delivered into the cytoplasm 27. Because of quaternary ammonium, PQ-10 cannot 
buffer the endosomal pH. To investigate whether the low transfection efficiency of PQ-10
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was in part attributed to a lack of endosomal escape of the polyplexes, we tested 
compounds known to improve the cytosolic delivery of macromolecules after their cellular 
uptake by the endosomes. Chloroquine is a lysosomotropic agent thought to have a 
buffering capacity preventing endosomal acidification27. In addition, it can lead to swelling 
and bursting of the endosomes and was shown to enhance DNA transfection 28,29,30. 
However, co-incubation of the COS-7 cells with 100µM chloroquine did not improve the 
transfection activity by PQ-10/pDNA complexes (data not shown). In a second approach, a 
membrane disrupting peptide derived from the influenza virus (INF-7) was used, which is 
known to destabilize endosomal membranes (facilitating the escape of the viral particles 
from the endosomes) 31. While other studies have shown that INF-7 significantly enhances 
the trancfection activity in COS-7 cells 31,32, addition of this peptide to PQ-10/pDNA 
polyplexes did not improve their transfection behaviour (data not shown). These data 
indicate that the lack of endosomal escape is probably not the major reason for the low 
transfection activity of PQ-10/DNA nanoparticles.
pDNA Release from Cationic Cellulose
Another critical step for obtaining successful transfection is the intracellular release 
of the pDNA from its carrier. While the pDNA has to remain associated with its carrier as 
long as it is outside the cells, intracellularly it has to release its carrier. In other words, a 
critical balance between being associated extracellularly and becoming dissociated 
intracellularly has to be maintained. To obtain information on ‘the ease of disassembling’ of 
the complexes we studied in buffer to which extent pDNA could be displaced from the 
complexes by the polyanions poly-L-aspartic acid and dextran sulfate. Their disassembling 
behavior was studied using agarose gel electrophoresis and a fluorescence dequenching 
assay. 
After incubation of the polyplexes with an excess of p(Asp) gelelectrophoresis 
revealed that both linear and branched PEI almost completely released the pDNA (Fig. 8A). 
In contrast, PQ-4 only partially released the pDNA whereas PQ-10 did not release pDNA at all 
(Fig. 8B), suggesting a stronger binding of pDNA to cationic celluloses than to PEI. Similar 
results were obtained when dextran sulfate was added to the cationic cellulose/pDNA
nanoparticles (data no shown). Fluorescence dequenching experiments (Fig. 9) show that 
upon adding p(Asp) all the pDNA is released from the PEI based complexes, in agreement 
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with the gelelectrophoresis results in Figure 8A. Also, p(Asp) (almost) completely releases 
pDNA from the PQ-4/pDNA complexes which does fully agree with the outcome of the 
gelelectrophoresis experiments in Figure 8B which suggested that the pDNA was only 
partially released at higher N/P ratios. Possibly p(Asp) only “partially” disassembles PQ-
4/pDNA complexes in the sense that the pDNA molecules become fully accessible for 
picogreen without becoming really released from the cationic cellulose polymers. 
Importantly, the fluorescence dequenching experiments in Figure 9 indicate that PQ-
10/pDNA complexes cannot be destabilized by p(Asp) in full agreement with the 
observations in the gelelectrophoresis experiments in Figure 8B. 
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Figure 8. Gelelectrophoresis on dispersions of (A) BPEI/pDNA and LPEI/pDNA complexes and (B) PQ-
4/pDNA and PQ-10/pDNA complexes. p(Asp) was added to the dispersions. The N/P ratio of the 
complexes was varied. 
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Figure 9. Fluorescence of (picogreen containing) cationic cellulose/pDNA and PEI/pDNA dispersions 
after adding p(Asp). The N/P ratio of the complexes was varied. 
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CONCLUSION
We have studied the physicochemical and transfection properties of PQ-4/pDNA and 
PQ-10/pDNA nanoparticles and compared them with DNA nanoparticles based on 
respectively branched and linear PEI. Gelelectrophoresis and fluorescence experiments 
indicated that PQ-4 can bind and condense pDNA, through stronger interactions than PEI.
The resulting PQ-4/pDNA nanoparticles are approximately 200 nm in size and have a neutral 
zeta-potential which is explained by the fact that the sugar backbone of PQ-4 bears, besides 
polycation side chains, also PEG side chains. We observed that PQ-4/pDNA nanoparticles do 
not transfect COS-7 and Hela cells which we attribute to their neutrally charged surface 
which does not allow an optimal binding of PQ-4/pDNA nanoparticles to cellular 
membranes, thus preventing an efficient cellular uptake. Developing a PQ-4 like cationic 
cellulose with a lower degree of pegylation might improve the transfection properties of PQ-
4/pDNA nanoparticles.
PQ-10/pDNA nanoparticles have a positively charged surface. Gelectrophoresis 
experiments indicated that PQ-10 binds pDNA stronger than PEI and PQ-4. However, upon 
binding to PQ-10 pDNA does not completely condense as picogreen can still, to a certain 
extent, intercalate in the pDNA. Although the PQ10/pDNA nanoparticles are positively 
charged, and thus expected to be taken up by cells, they are much less efficient in 
transfecting cells than PEI/pDNA nanoparticles. Agents known to enhance the endosomal 
escape (like chloroquine and the INF-7 peptide) were not able to improve the transfection 
properties of PQ-10/pDNA nanoparticles indicating that a poor endosomal escape is, highly 
likely, not the major reason for the low transfection activity of PQ-10/pDNA nanoparticles. 
Based on our findings we hypothesize that the strong binding of pDNA to PQ10 inhibits the 
release of pDNA from PQ-10 once the PQ-10/pDNA nanoparticles arrive in the cytosol of the 
cells. As the PQ-10/pDNA nanoparticles did transfect the cells to a certain extent, although 
less efficient than PEI/pDNA nanoparticles, tailoring of the nature and extent of cationic side 
chains on this type of cationic hydroxyethylcellulose may be promising to further enhance 
their DNA delivery properties.
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ABSTRACT
To obtain more biologically relevant data there is a growing interest in the use of 
living cells for assaying the biological activity of unknown chemical compounds. Density 
“multiplex” cell-based assays, where different cell types are mixed in one well and 
simultaneously investigated upon exposure to a certain compound are beginning to emerge. 
To be able to identify the cells they should be attached to microscopic carriers that are 
encoded. This paper investigates how digitally encoded microparticles can be loaded with 
cells keeping the digital code in the microcarriers readable. It turns out that coating the 
surface of the encoded microcarriers with polyelectrolytes using the Layer-by-Layer (LbL) 
approach provides the microcarriers with a “highly functional” surface. The polyelectrolyte 
layer (a) allows the growth of the cells (b) allows the orientation of the cell loaded 
microcarriers in a magnetic field and (c) does not hamper the reading of the code. We 
conclude that the digitally encoded microparticles are promising materials for use in 
biomedical and pharmaceutical in vitro research where cells are used as tools.
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INTRODUCTION
Due to significant progress in combinatorial chemistry the synthesis of huge libraries 
of drug candidates is no longer a bottleneck in the drug discovery process. However, 
screening the biological activity of these numerous compounds at high throughput remains 
very challenging. Historically, “biochemical assays” were often employed to screen the 
interaction between unknown compounds and targets in solution. To obtain more 
biologically relevant data from screening work, there is a growing interest in the use of living 
cells for assaying the biological activity of unknown compounds as this approach is better 
suited for the complex biology surrounding the target molecules 1. For example, because a 
majority of today’s drugs target G-protein-coupled receptors (GPCRs) in the cell membranes, 
major efforts have been made to develop cell-based, high throughput assays that screen 
compounds for their interaction with GPCRs 2,3. Typically, in such cellular assays, the 
response of living cells (e.g. the calcium flux in the cells or the activation of a reporter gene) 
upon exposure of the cells to an unknown compound is measured to detect GPCR responses. 
Initially, cell based assays were performed in the wells of microtiter plates. Typically, 
each well contained one type of cells that were exposed to a certain compound. In an 
attempt to increase data density and quality and to save time and reagents, “multiplex” cell 
based assays are beginning to emerge. In “multiplex cellular assays” different cell types are 
mixed in one well and simultaneously investigated upon exposure to a certain compound. 
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In general, multiplex technologies are divided in two categories; "positional arrays" 
(also named “flat surface arrays”) 4-9 and "non positional arrays" (also named “suspension 
arrays”) 10-16. A positional cell array offers a format without wells for high-throughput cell 
based assaying; the identity of each cell is determined by its x,y-position on the array. As the 
name implies, non positional cell arrays do not rely on the location of a cell on an array to 
identify the cell type but on a "code" written in a (micro) particle which carries the cell. Each 
cell type is thus grown on an encoded microcarrier and therefore physically associated with 
the code of this microcarrier. It is believed that non positional arrays have greater flexibility 
and require smaller sample volumes compared to positional arrays 16. Non positional arrays 
are not only of interest for multiplex cell based assaying but also for multiplex protein and 
nucleic acid assaying. Various strategies have been applied to encode microparticles: 
spectrometric encoding 17,18, electronic encoding 19,20, physical encoding 21,22 and graphical 
encoding 23-25.
Interesting information on the growth of (normal and genetically engineered) 
mammalian cells on the surface of non-encoded microcarriers is available 26 . Cell loaded 
microcarriers (based on e.g. cross-linked dextran or polystyrene) have been used for a long 
time, e.g. producing recombinant proteins (used as biopharmaceuticals in therapy and 
diagnostics) and viruses (used as vaccines) 26-28. Clearly, the surface of the microcarrier at 
physiological pH should supply sites which favour the attachment, spreading and 
proliferation of the cells. Also, the density of the microcarriers should not be too high 
because a settling down of the beads could possibly prevent cell growth. Furthermore, the 
size-distribution of the microcarriers should be narrow so that cells on the different 
microcarriers attain confluency at approximately the same time and, last but not least, the 
microcarriers should be non-toxic to the cells. 
To our knowledge there are only few reports which deal with the growth and the 
behaviour of cells on encoded microcarriers 29-32. This paper studies whether photophysically 
encoded microparticles, recently introduced by our group for various applications 33-35 and 
named “Memobeads”, are suitable to grow cells on. As shown in (Fig. 1B, 1C), 
photophysically encoded microparticles carry a digital code (like a dotcode or a barcode) in 
their middle plane. The code in a particular bead reads out which”sensing molecule”
or”probe” is bound to its surface. The probe can be an antibody (for screening antigens), a 
single stranded oligonucleotide (for single nucleotide polymorphism detection) or, in this 
EVALUATION OF DIGITALLY ENCODED LAYER-BY-LAYER COATED MICROPARTICLES AS CELL CARRIERS- CHAPTER 3
69
study, a cell. Before attaching the probe, we first applied at the surface of a Memobead a 
“Layer by Layer” (LbL) coating which is composed of polyelectrolytes (PEs) (Fig. 1A). ‘LbL 
coating’ is based on the alternate adsorption of oppositely charged PE’s (or charged 
nanoparticles) onto a charged substrate 36-39 LbL technology has raised considerable interest
40,41. A large variety of functionalized material such as DNA 42-46, drugs 47,48, proteins and 
peptides 49-51 can be incorporated into these assemblies. Therefore LbL films could play an 
important role in development of localized and controlled delivery of macromolecules. 
We reported previously that the polystyrene core of a Memobead can be successfully 
LbL coated with polycations (PAH =poly(allylamine hydrochloride)), polyanions (PSS = 
poly(styrene sulfonate)) and ferromagnetic chromium dioxide nanoparticles (CrO2 NP). As 
explained in detail by Derveaux et al. 33 the CrO2 NP allow an optimal positioning of the 
Memobeads in a magnetic field, which is necessary to read the code at the time of decoding 
(Fig. 1D). 
Figure 1. (A) Schematic representation of the LbL coating of green fluorescent polystyrene 
microspheres. The polycation PAH and the polyanion PSS are alternately adsorbed to the surface of 
the microcarrier. Magnetic CrO2 nanoparticles are immobilized in the LbL coating. (B,C) Confocal 
images of the central plane of fluorescent microspheres encoded with respectively a bar code (B) and 
a dot code (C). The scale bar represents 10 µm. (D) A correct orientation and position of the 
microsphere is required at readout time. At position D1, the code is tilted with respect to the 
microscope focal plane and only the intersection of the code with the focal plane is visible. At 
position D2 the entire code is visible because it coincides with the focal plane.
In the present study we aim to evaluate (a) whether cells can be grown on the 
magnetic LbL surface of digitally encoded microcarriers and (b) whether the cell layer at the 
surface does not hamper the decoding of the beads. Indeed, the heavy cell load might 
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prevent the orientation of the beads in a magnetic field while the fluorescence in the cells 
(due to the expression of a fluorescent reporter protein) may interfere with the optical 
reading of the code. Further we aim to evaluate (c) whether we can perform an ELISA assay 
on the cells at the LbL surface. The possibility to perform ELISA’s in the cells on the encoded 
microcarriers may be important tools for cell-based multiplexing with such encoded 
microcarriers.
MATERIALS & METHODS
Materials
Non-magnetic fluorescent carboxylated microspheres (CFP-40052-100, ø = 39 µm) 
were purchased from Spherotech (Libertyville, Illinois, USA). Poly (allylamine hydrochloride) 
(PAH; 70 kDa) and sodium poly (styrene sulfonate) (PSS; 70 kDa) were obtained from Sigma 
Aldrich (Steinheim, Germany). LysoTracker Red DND-99 was obtained from Molecular 
Probes. HEK-293 cells and Antibody against human IL5R-alpha were a kind gift of Prof. J. 
Tavernier (Ghent University). CHO-320 cells were a kind gift from Prof. Y.J. Schneider 
(Catholic University of Louvain). Cy5- goat anti- mouse IgG (H+L) conjugate was purchased 
from Zymed (San Francisco, CA). Leukemia Inhibitory Factor (LIF) was obtained from Sigma 
Aldrich (Steinheim, Germany). HEK-293, Vero-1, COS-7, Hela, HuH-7 and CHO cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Merelbeke, Belgium) 
containing 2 mM L-glutamine (L-Gln), 10% heat inactivated fetal bovine serum (FBS) and 1% 
penicillin-streptomycin (P/S). 
Layer-by-Layer coating of the microcarriers
The polystyrene microspheres were coated with the polyelectrolytes PSS and PAH as 
reported previously 33. The microspheres were LbL coated by suspending them in 1 ml (2 
mg/ml) PAH solution (prepared in 0.5 M NaCl); the suspension was continuously vortexed 
(1000 rpm, 25°C) for 15 min. The non-adsorbed PAH was removed by repeated 
centrifugation and washing. Subsequently, the microspheres were dispersed in deionised 
water containing sub 500 nm CrO2 NP. The CrO2 NP are used to position the microspheres in 
a magnetic field to allow the reading of the code, as described in detail elsewhere 33. The 
microsphere dispersion was continuously shaken for 15 min and the excess of CrO2 NP was 
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removed by repeated centrifugation/washing steps. The third, fourth… polyelectrolyte layer 
was applied in a similar way as the first layer. Finally as illustrated in Figure 2(A) the 
microspheres were coated with 5 or 6 layers in the following order: PAH / sub 500 nm CrO2 
NP / PAH / PSS / PAH / PSS. Then resulting LbL coated microspheres were resuspended in 1 
ml of ultrapure demiwater (± 400 000 microspheres/ml) and subsequently encoded (see 
below).
Growing cells on the microcarriers
The LbL coated (encoded) beads were dispersed in cell culture medium (DMEM 
containing about 50 % bovine serum). An appropriate volume of the microsphere dispersion 
(approximately 100 µl) was applied in polycarbonate Erlenmeyer shake-flasks (Corning) that 
were treated with a silicone solution (Sigmacoat®; Sigma) following the manufacturer’s 
protocol. The silicone treatment should prevent the attachment of cells to the surface of the 
flasks. Subsequently, an appropriate amount of cell suspension (in DMEM supplemented 
with 2% P/S, 1% L-GLn and 10% FBS) was added to the flasks for 3 hours at 37°C and 5% CO2
to allow the attachment of cells to the surface of the beads. During this 3 hours period the 
flasks were not shaken to allow the initial attachment of the cells. Subsequently we began to 
agitate the flasks on an orbital shaker under appropriate conditions to prevent the 
precipitation of the microcarriers, which prevents an optimal cell growth. Typically after one 
night the cell loaded microcarriers were used for further examination. 
Encoding of the microcarriers
The LbL coated microspheres were encoded by spatial selective photobleaching as 
previously described 23. An in-house-developed encoding device was used, being a 
microscopy platform equipped with an Aerotech ALS3600 scanning stage, a SpectraPhysics 
2060 Argon laser and an Acousto-Optic-Modulator (AA.MQ/A0.5-VIS, A.A-Opto-Electronique, 
Orsay Cedex, France). The encoding process consists of two steps, a writing step (i.e. the 
photobleaching process) and a magnetizing step, during which the CrO2 loaded microspheres 
are exposed to an external magnetic field sufficient to provide them with a magnetic 
memory. The microspheres were fixed on a grid during the encoding process to prevent 
rotation between the two steps. 
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Decoding of the cell loaded microcarriers
The cell loaded microspheres were decoded using a confocal laser scanning 
microscope (CLSM using a Bio-Rad MRC1024) equipped with a 60x water immersion 
objective lens. To visualize the beads and to read their code upon magnetic orientation an 
excitation light of 488 nm was used. To visualize the fluorescence in the cells at the surface
of the microcarriers, excitation wavelengths of 567 nm and 647 nm were used. 
Autoclaving of the microcarriers
A sample of encoded microcarriers was autoclaved for 20 min. These encoded 
microcarriers were decoded by the use of a confocal microscope as described above.
Cell toxicity of the microcarriers
The cell toxicity of the Memobeads was evaluated by the EZ4U assay (Biomedica 
GmbH, Vienna, Austria) 52. A large amount of LbL coated microcarriers (> 106) was dispersed 
for 48, 72 and 140 hours in cell culture medium. In this way, compounds that are possibly 
present in the LbL coating and the polystyrene core of the microcarriers, and which may be 
toxic to cells, were “extracted” in the cell culture medium. Cells were subsequently grown in 
the cell culture medium obtained in this manner. An EZ4U test was performed in the 
exponential phase of growth. Briefly, 50 µl of EZ4U substrate, together with 450 µl culture 
medium, was added to each well and incubated for 2-5 hours. The absorbance was 
measured with a Wallac Victor2 absorbance plate reader (Perkin Elmer; Waltham, MA) set at 
450 nm with a reference wavelength of 620 nm. Negative and positive control experiments 
were included by using cell culture medium that had not been exposed to Memobeads and 
by using cell culture medium that was supplemented with 10 mg/ml of phenol, respectively. 
Detecting ligand responsive cells on encoded microcarriers
HEK-293 FlpIn cells (Invitrogen) stably expressing a STAT3-responsive rPAP1-
hIL5Ralpha deltacyt reporter 53 were cultured in DMEM containing glutamine supplemented 
with 10% FBS and 2% P/S. The HEK-293 cells were stimulated with 10 ng/ml Leukemia 
Inhibition Factor (LIF) for 24 hours. Upon confluency, the stimulated cells were trypsinized 
and were grown on the beads as described above. The cell loaded microcarriers were 
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incubated at 4°C in a 1 µg/ml of primary antibody solution (against human IL5R-alpha.) 54. 
After 20 min incubation the antibody was removed by washing with culture medium. 
Subsequently the cell loaded microcarriers were incubated at 4°C with fluorescently labeled 
secondary antibody (Cy5- goat anti- mouse IgG (H+L) conjugate). After 20 min incubation the 
antibody was removed by washing with culture medium and the cells on the microcarriers 
were checked by fluorescence microscopy.
RESULTS & DISCUSSION
Autoclaving of encoded microcarriers
To allow the growth of cells on the surface of the encoded microcarriers, it is 
necessary to use sterile samples of encoded microcarriers. Therefore, a dispersion of 
encoded microcarriers was autoclaved and we ascertained that autoclaving neither destroys 
the code inside, nor the LbL surface of the microcarriers. As Figure 2 shows, we could still 
observe the code in the autoclaved microcarriers, indicating that autoclaving does not 
destroy the polystyrene matrix of the microcarriers. It also indicates that autoclaving did not 
destroy the LbL coating and the magnetic orientation of the chromium dioxide 
nanoparticles. Remember, changes in the LbL coating or displacement of the magnetic 
nanoparticles would have no longer allowed a good positioning of the beads in the magnetic 
field, thereby making the read-out of the code impossible. 
A B
Figure 2. Confocal image of the central plane of (dot) encoded microcarriers respectively (A) before 
and (B) after autoclaving. The code is written in the green fluorescently dyed microspheres (about 40 
µm in diameter) by local photobleaching of the dye. 
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Cell toxicity of the microcarriers
As described in the materials and methods section, a monolayer of cells was cultured 
in an extract of the microcarriers and the cytotoxicity of this extract was evaluated. The cells 
survived well (Fig. 3) indicating that the LbL encoded microcarriers do not release toxic 
compounds in sufficient amounts to kill the cells.
Figure 3. Toxicity of a “Memobead extract” for Vero-1 and A549 cells. Data represent the mean 
values obtained on three independently prepared samples ± SD compared to the appropriate 
control.
Growing cells on encoded microspheres
First we investigated to what extent CHO-320, Vero-1, Hela, COS-7 and HuH-7 cells 
can be cultured on the surface of LbL coated encoded microcarriers. As Figures 4 and 5 
show, all these mammalian cells grew on the encoded microcarriers, though differences in 
the growth of the cells could be observed. Once attached to the microcarriers, HuH- 7 and 
CHO-320 cells grew quickly while Vero-1 cells needed a longer time to completely cover the 
surface of a microcarrier with a single cell layer. When the encoded microcarriers were 
incubated for longer times with the cells, the surface of the microcarriers became covered 
with multiple cell layers (Fig. 4, bottom row).
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A B C
Figure 4. Microscopy images of Vero-1 cells grown on the surface of LbL coated microcarriers. (A)
Transmission image, (B) green fluorescence image (λex 488 nm) and (C) merged green/red 
fluorescence image (λex 488 nm and 567nm). The cytosol of the Vero-1 cells was colored red using
LysoTracker Red. Note that non-encoded beads (about 40 µm in diameter) were used. Bottom row 
shows the overgrowing of cell after longer incubation.
Figure 5. (A-E) Confocal merged green/red fluorescence images (λex 488 nm and 567 nm) of (A) Vero-
1, (B) CHO, (C) HELA, (D) HuH-7 and (E) COS-7 cells grown on the surface of LbL coated microcarriers. 
(F) Image of CHO cells loaded beads at lower magnification. The cytosol of the cells was colored red 
using LysoTracker Red. Note that non-encoded beads were used. The scale bar represents 10 µm in 
images A to E and 50 µm in image F.
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Though we did not encounter real problems in growing CHO-320, Vero-1, Hela and 
HuH-7 cells on the encoded microcarriers, it may be less straightforward to grow other cell 
types. However, we would like to point out that LbL technology is highly flexible and easily 
allows adapting the surface properties for optimal cell growth. The attachment and 
proliferation of cells on polyelectrolyte flat membranes were recently nicely demonstrated 
55,56. Attractive and new in this study is that cells were grown on a magnetic polyelectrolyte 
surface which is highly functional in the sense that the LbL coating serves both as cell 
support layer and to orient of the microcarriers. 
Decoding of cell loaded microcarriers
For decoding, the cell loaded microcarriers still have to be oriented. Also, one could 
wonder whether the cell layer surrounding the microcarrier does not optically interfere with 
the readout of the code Importantly, although the surface of the beads was covered with 
cells, we found that the orientation of the beads was not hampered and the code inside the 
beads remained perfectly detectable by confocal laser scanning microscopy, as shown in 
Figure 6. 
Figure 6. Confocal merged green/red fluorescence images (λex 488 nm and 567nm) of Vero-1 cells 
grown on the surface of a (dot) encoded LbL coated microcarrier. In the magnetic field the 
microcarrier takes a correct position which makes the code readable. Arrow 1 indicates the cytosol of 
the Vero-1 cells which was colored red using LysoTracker Red, arrow 2 shows the nucleus of the cells. 
In the supplementary information one can find a movie which shows a z-scan of a Vero-1 cell loaded 
(encoded) microcarrier. 
Figure 6 shows that a red colouring in the cytosol of the Vero-1 cells does not 
compromise the decoding of the beads. In a next step we wondered whether green 
fluorescence in the cells covering the microcarriers, which may be the case when the cell 
loaded microcarriers are used in assays, would not interfere with the decoding of the beads. 
Therefore, green fluorescent protein (GFP) expressing Vero-1 cells (Fig. 7) and red 
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fluorescent protein (RFP) expressing CHO-320 cells (data not shown) were grown on the 
encoded microcarriers. We observed that the code inside the beads remained detectable 
even when the cells covering the microcarriers exhibited green or red fluorescence. 
Figure 7. (A) Transmission and (B) confocal green fluorescence (λex 488 nm) images of (dot) encoded 
LbL coated microcarriers loaded with GFP expressing Vero-1 cells. 
Detecting ligand responsive cells on encoded microcarriers
In a next step we evaluated whether we could perform an ELISA assay on the cells that 
were grown on the surface of the encoded microcarriers. Therefore, Leukemia Inhibition 
Factor (LIF) responsive HEK-293 cells were grown on encoded microparticles upon LIF 
treatment. The expressed surface tag on these cells could be detected by use of a tag-
specific antibody and a secondary (red fluorescently labeled) antibody (see Fig. 8). Note that 
beads covered with non-responsive HEK-293 cells did not show any red fluorescence (data 
not shown). The data in Figure 8 demonstrate that cell based ELISA assays can be performed 
on cells grown on the LbL coated encoded microcarriers.
Figure 8. (A) Transmission and (B) red fluorescence (λex 567 nm) images of LbL coated microcarriers 
loaded with LIF-responsive HEK-293 cells. The cells were treated with LIF resulting in the expression 
of a surface tag which was visualized by means of red fluorescently labeled antibodies. 
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CONCLUSION
In summary, this study shows that CHO-320, Vero-1, Hela, COS-7, HuH-7 and HEK-293
cells can be cultured at the surface of digitally encoded microcarriers coated with a number 
of layers of polyelectrolytes. Coating of the microcarrier’s surface by LbL technology is highly 
flexible as it is straightforward to adapt the physicochemical composition of the coating with 
the aim to optimize the growth of a certain cell type. Incorporation of ferromagnetic 
chromium dioxide nanoparticles (CrO2 NP) in the LbL coating allowed positioning of the 
microcarriers in a magnetic field, though they were heavily loaded with cells. The LbL coating 
serves as a cell supporting layer as well as to orient the microcarriers. We observed that the 
code inside the microcarriers remained readable even when the cells covering the 
microcarriers exhibited green or red fluorescence due to the expression of GFP and RFP 
respectively. It was also shown that tags expressed on the surface of the cells on the 
microcarriers could be detected by use of a tag-specific antibody and a secondary (red 
fluorescently labeled) antibody demonstrating that cell-based ELISA assays can be 
performed on cells grown on the LbL coated encoded microcarriers
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ABSTRACT
”Reverse transfection” cells with pDNA or siRNA has been proposed as a useful tool for the 
simultaneous high-throughput analysis of the function of many different genes on a solid 
surface. The aim of the present work is to evaluate whether encoded microcarriers, coated 
with polyelectrolyte multilayers, are suitable to immobilize naked nucleic acids, non-viral 
nucleic acid complexes and viruses and whether the cells which grow at the surface of the 
microcarriers become (“reversely”) transfected.
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Layer Coated Microparticles for Reverse 
Transfection
INTRODUCTION
Technologies which allow efficient delivery of nucleic acids, such as plasmid DNA
(pDNA), oligonucleotides and small interfering RNA (siRNA), are of major importance both in 
basic biological sciences as well as in clinical medicine. Generally speaking, both viral and 
non-viral nucleic acid carriers are currently under development. Viral vectors, such as for 
example retroviruses and adenoviruses, are still the most efficient nucleic acid delivery 
vehicles 1-4, however, cytotoxicity, immunogenicity and mutagenesis of transfected cells are 
major concerns 5. Non-viral vectors like polymers and liposomes 6-8, which are mostly 
cationic in nature and therefore spontaneously assemble with negatively charged nucleic 
acids, have attracted major interest for the safe delivery of therapeutic nucleic acids into 
target cells 9,10, however, their application in vivo remains currently limited due to their poor 
efficacy 11,12.
In most in vitro transfection studies typically nucleic acids, either in ”naked” form or 
complexed to carriers, are added to cells which are growing e.g. at the bottom surface of 
wells of microtiterplates. Recently, immobilizing DNA onto a solid surface prior to cell 
seeding, with the aim of transfecting the seeded cells has been proposed. This method is 
termed “solid-phase nucleic acid delivery” 13,”reverse transfection” 14 or”substrate 
mediated nucleic acid delivery” 15,16 as schematically represented in panel A of Figure 1. A 
possible advantage of this approach is that the cells are in closer contact with highly 
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concentrated spots of (immobilized) nucleic acids which may improve the transfection 
efficiency. 
In general, a successful reverse transfection necessitates both an appropriate 
immobilization of the nucleic acids on the surface as well as an appropriate release of the 
nucleic acids from the surface into the cells. Different strategies were developed to 
immobilize naked nucleic acids or (non-) viral nucleic acid complexes on cell culture surfaces 
such as the entrapment of the nucleic acids in a thin gelatin film deposited on the surface 14, 
specific binding of the nucleic acids to the surface through the biotin-avidin interaction 15-19
and immobilization through non-specific adsorption 20-22. 
Recently, immobilizing nucleic acids in polyelectrolyte coatings deposited on 
surfaces, to allow reverse transfection, has been proposed as well 23,24. Such polyelectrolyte 
coatings are deposited on the surface by the so named ”Layer-by-Layer” (LbL) technology 
which is based on the sequential adsorption of oppositely charged polyelectrolytes on a 
charged planar substrate. Upon adsorption of a polyelectrolyte layer, charge 
overcompensation takes place, leading to a reversal of the surface charge, promoting the 
adsorption of a next, oppositely charged, polyelectrolyte. As an example, is has been shown 
that a polyelectrolyte film, also named LbL film, composed of naked (negatively charged) 
pDNA and (bio) degradable (positively charged) polyamines allow the (gradual) release of 
pDNA from the coating through (gradual) breakdown of the polyamines 24,25. As another 
example, Jessel et al. have shown that LbL films composed of poly(L-glutamic acid), poly(L-
lysine) and charged cyclodextrins can release entrapped plasmid DNA which transfects the 
cells growing on the LbL films 26. Besides naked DNA also nucleic acid/cationic polymer 
complexes 27,28 and viral vectors 29 can be immobilized in LbL films.
“Reverse transfection”, may become a useful research tool in e.g. cell-based 
microarrays. An advantage of the reverse transfection approach is its multiplex capacity: 
whole libraries of nucleic acids can be easily and simultaneously screened on (a broad range 
of) cells. Ziauddin and Sabatini have recently created a transfected cell microarray (panel A 
in Figure 1) with the aim to identify the cellular functions of the immobilized genes 14. Such 
cell-based microarrays show spots of (mammalian) cells expressing the DNA constructs 
immobilized at those spots. Similarly, recombinant viral vector libraries 30-33 can be arrayed 
by spotting the viruses on a solid surface onto which cells are subsequently plated. This 
should result in an array of cells, expressing the recombinant genes of interest. The reverse 
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transfection approach was also used to knock down genes in the plated cells; Indeed, 
Mousses et al. arrayed spots (hundreds of micrometers in size) of synthetic siRNAs on glass 
slides for parallel knockdown of different genes 34. 
In this chapter we aimed to evaluate whether reverse transcription can be obtained 
from nucleic acids immobilized at the surface of (encoded) microcarriers with the overall 
goal to develop an “encoded microcarrier based reverse transfection assay”, as 
schematically illustrated in panel B of Figure 1. The two specific questions which we 
considered were the following: (a) Are LbL coated encoded beads suitable to immobilize 
respectively viral vectors, naked nucleic acids and complexed nucleic acids? (b) Are the 
adenoviral particles and nucleic acids immobilized in the LbL coatings at the surface of the 
beads able to selectively transfect the cells that grow on top of the LbL coated 
microcarriers?
Cells
Assay
A
Cells
CODE 
1
CODE 
3
CODE 
2
Assay
B CODE 
1
CODE 
1
DNA is transferred to a solid 
surface using a robotic 
spotter 
DNA loading on encoded 
microcarrier
Figure 1. Reverse transfection of cells. (A) Schematical presentation of a DNA-microarray for the 
reverse transfection of cells. DNA is spotted onto a solid surface, each spot contains another type of 
DNA, the x,y-coördinate of the spot allows to identify which type of DNA is present at a specific 
location on the array. Subsequently cells are seeded and start to attach to the surface of the DNA 
microarray. DNA is released from the surface and only taken up by those cells that attach to regions 
where DNA is present. The transfected cells will express the protein corresponding to the DNA taken 
up by the cells. (B) Schematical presentation of an encoded microcarrier based reverse transfection 
assay. The DNA is applied on the surface of encoded microcarriers, the code in the carrier allows to 
identify which DNA is at the surface of a specific carrier. The DNA carrying beads are applied in a cell 
suspension; cells start to grow on the surface of the beads followed by reverse transfection of the 
cells.
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MATERIALS & METHODS
Materials
Non-magnetic fluorescent carboxylated microspheres (CFP-40052-100, ø = 39 µm) 
were purchased from Spherotech (Libertyville, Illinois, USA). Poly (allylamine hydrochloride) 
(PAH; 70 kDa) and sodium poly (styrene sulfonate) (PSS; 70 kDa) were obtained from Sigma 
Aldrich (Steinheim, Germany). 4,4’-trimethylenedipiperidine and anhydrous 
dichloromethane (CH2Cl2) were purchased from Sigma-Aldrich (Bornem, Belgium). 1,4-
Butanediol diacrylate was purchased from Alfa Aesar Organics (Karlsruhe, Germany). 1,2-
Dioleolyl-3-trimethylammoniumpropane (chloride salt) (DOTAP), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids (AL, USA). Linear 
poly (ethylene imine) (LPEI, MW 22 KDa) was a kind gift from Prof. E. Wagner (Ludwig 
Maximilian University, Munich, Germany). The recombinant adenoviral vectors Ad-RFP and 
Ad-GFP, which express the red fluorescent protein (RFP) and green fluorescent protein 
(GFP) respectively, were obtained from Vector Biolabs (Philadelphia, USA). CHO-320 cells 
were a kind gift from Prof. Y.J. Schneider (Catholic University of Louvain). Vero-1 and CHO 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Merelbeke, 
Belgium) containing 2 mM L-glutamine (L-Gln), 10% heat inactivated fetal bovine serum 
(FBS) and 1% penicillin-streptomycin (P/S). HuH-7_eGFPLuc cells stably expressing eGFP-
luciferase were generated by transfecting HuH-7 cells with the vector pEGFPLuc (Clontech, 
Palo Alto, USA) as previously described 37. DsRed2-C1 pDNA was obtained from Promega 
(Leiden, The Netherlands), amplified in Escherichia coli and purified by the Qiagen Plasmid 
Mega Kit (Venlo, The Netherlands). TOTO-3 was purchased from Invitrogen for labeling the 
pDNA. siRNA against EGFP and Dsred, ”negative” siRNA (used in control experiments) and 
Cy5 labeled  siRNA were purchased from Dharmacon (Chicago, USA). All siRNAs were 
purchased in their annealed form, dissolved in RNase free water at the concentration of 20
μM, aliquoted and stored at -80°C.
Layer-by-Layer (LbL) coating of the microcarriers
The polystyrene microspheres were coated with the polyelectrolytes PSS and PAH as 
reported previously 35. Briefly, the microspheres were suspended in 1 ml PAH solution (2 
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mg/ml in 0.5 M NaCl) and continuously vortexed (1000 rpm, 25°C) for 15 min. The non-
adsorbed PAH was removed by repeated centrifugation and washing. Subsequently, the 
microspheres were dispersed in deionised water containing CrO2 nanoparticles (NPs, 
<500nm). The CrO2 NPs are necessary to position the microspheres in a magnetic field to 
allow the reading of the code, as described in detail elsewhere 35. The microsphere 
dispersion was continuously shaken for 15 min and the excess of CrO2 NPs was removed by 
repeated centrifugation/washing steps. The next polyelectrolyte layers were applied 
similarly. As illustrated in Figure 2, the microspheres were coated with 5 or 6 layers in the 
following order: PAH / CrO2 NP / PAH / PSS / PAH / PSS. Finally, the resulting LbL coated 
microspheres were resuspended in 1 ml of ultrapure demiwater at ± 400 000 
microspheres/ml and subsequently encoded.
Encoding of the microcarriers 
The LbL coated microspheres were encoded by spatial selective photobleaching as 
described previously 36. Briefly, an in-house-developed encoding device was used, being a 
microscopy platform equipped with an Aerotech ALS3600 scanning stage, a SpectraPhysics 
2060 Argon laser and an Acousto-Optic-Modulator (AA.MQ/A0.5-VIS, A.A-Opto-
Electronique, Orsay Cedex, France). The encoding process consists of two steps, a writing 
step (i.e. the photobleaching process) and a magnetizing step, during which the CrO2 loaded 
microspheres are exposed to an external magnetic field sufficient to provide them with a 
magnetic memory. The microspheres were fixed on a grid during the encoding process to 
prevent rotation between the two steps. 
Synthesis of PbAE1 
PbAE1 was synthesized as described previously 37. Briefly, 37.8 mmol 1,4-butanediol 
diacrylate and 37.8 mmol 4,4’-trimethylenedipiperidine were separately dissolved in 50 ml 
CH2Cl2. The 4,4’-trimethylenedipiperidine solution was added dropwise to the 1,4-
butanediol diacrylate solution under vigorous stirring. The reaction mixture was placed in an 
oil bath at 50°C and the polymerisation was allowed to proceed during 48 h under a 
nitrogen atmosphere. After cooling to room temperature, the reaction product was 
precipitated in diethyl ether saturated with HCl. The precipitate was filtered and thoroughly 
washed with diethyl ether. A white powder was obtained after overnight drying under 
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vacuum. Subsequently, the polymer was dissolved in acetate buffer (100 mM, pH 5.4) at a 
stock solution concentration of 0.5 mg/ml and filtered through a 0.22 µm membrane syringe 
filter prior to use.
Preparation of cationic liposomes
Cationic liposome composed of DOTAP:DOPE in a 1:1 molar ratio were prepared as 
described previously 38. Briefly, lipids were dissolved in chloroform and mixed. The 
chloroform was subsequently removed by rotary evaporation at 37°C followed by flushing 
the obtained lipid film with nitrogen during 30 min at room temperature. The dried lipid film 
was then hydrated by adding Hepes buffer (20 mM, pH 7.4) till a final lipid concentration of 
10 mM. After mixing in the presence of glass beads, liposome formation was allowed 
overnight at 4°C. Thereafter, the formed liposomes were extruded 11 times through two 
stacked 100 nm polycarbonate membrane filters (Whatman, Brentfort, UK) at room 
temperature using an Avanti Mini-Extruder (Avanti Polar Lipids).
Preparation of polyplexes 
Polyplexes consisting of 22 kDa linear PEI were prepared as optimized previously 39. 
Briefly, polyplexes were prepared in 20 mM Hepes pH 7.4 by adding different volumes of 
the polymer stock solution (0.5 mg/ml), dependent on the desired N/P ratio (10), at once to 
the pDNA solution. Subsequently, the mixture was vortexed for 10 sec and allowed to 
equilibrate for 30 min at room temperature prior to use. The final pDNA concentration in 
the polyplex dispersion was 0.126 µg/µl.
Preparation of lipoplexes
The extruded liposomes were mixed with pDNA, in a +/- charge of 4, the +/- charge 
ratio being defined as the ratio of the number of the positive charges (originating from 
DOTAP) to the number of the negative charges (originating from the pDNA). This mixture 
was then vortexed and incubated at room temperature for 30 min. The final concentration 
of pDNA in the lipoplex dispersion was 0.126 µg/µl. 
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Preparation of PbAE1:siRNA complexes
PbAE1:siRNA complexes at an N:P ratio of 30:1 were formed by mixing equal 
volumes of a PbAE1 solution and a 0.5 µM siRNA solution, followed by vigorously mixing. 
The resulting PbAE1:siRNA complexes were incubated at room temperature for at least 
30 min before addition to the cells.
Size and zeta potential measurements
The average particle size and the zeta potential () of the liposome, lipo- and 
polyplexes were measured by photon correlation spectroscopy (PCS) (Autosizer 4700, 
Malvern, Worcestershire, UK) and particle electrophoresis (Zetasizer 2000, Malvern, 
Worcestershire, UK), respectively. The liposome, lipoplex and polyplex dispersion were 
diluted 40-fold in 20 mM Hepes buffer pH 7.4 while the PbAE:siRNA dispersion was diluted 
2-fold in 0.1 M acetate buffer pH 5.4 prior to particle size and zeta potential measurements. 
The average (±standard error) size of the liposomes and lipoplexes was 134  2 nm and 228 
 2 nm, respectively. Their average  equalled 52  2 mV and 46 3 mV, respectively. The 
size and  of the linear PEI polyplexes were 165 ± 4 nm and 33 ± 2 mV. The size and  of the 
PbAE:siRNA complex equalled 380 ± 9 nm and 31 ± 1 mV.
Immobilizing naked pDNA, polyplexes, lipoplexes, naked siRNA, PbAE:siRNA complexes 
and adenoviral particles at the surface of the encoded beads
For immobilizing adenoviral particles, naked or complexed nucleic acids, an 
appropriate amount of sample was added to a 10 µl dispersion of LbL coated (encoded) 
microcarriers in DMEM. The mixture was continuously vortexed (1000 rpm, 25°C) for 3 h. 
Subsequently, the microcarriers were separated from the (non adsorbed) free adenoviral 
particles or nucleic acids by repeated centrifugation and washing with DMEM (3 times). Cells 
were then grown on the loaded microcarriers as described below. 
Growing cells on the microcarriers and reverse transfection 
The LbL coated (encoded) beads, loaded with adenoviral particles or nucleic acids, 
were dispersed in cell culture medium (DMEM containing about 50 % FBS). Approximately 
100 µl volume of the microsphere dispersion was applied in polycarbonate Erlenmeyer 
shake-flasks (Corning) that were treated with a silicone solution (Sigmacoat®; Sigma) 
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following the manufacturer’s protocol. The silicone treatment should prevent the 
attachment of cells to the surface of the flasks. Subsequently, an appropriate amount of cell 
suspension (in DMEM supplemented with 2% P/S, 1% L-GLn and 10% FBS) was added to the 
flasks for 3 h at 37°C and 5% CO2 to allow the attachment of cells to the surface of the 
beads. During this 3 h period the flasks were not shaken to allow the initial attachment of 
the cells. Subsequently we began to agitate the flasks on an orbital shaker under 
appropriate conditions to prevent the precipitation of the microcarriers. After 24 h the 
microcarriers carrying cells were studied under the microscope (CLSM; Bio-Rad MRC1024) to 
evaluate to which extent the cells became transfected or transduced. 
Decoding of the cell loaded microcarriers
The cell loaded microspheres were decoded using a Bio-Rad MRC1024 microscope 
equipped with a 60x water immersion objective lens and a magnet. To visualize the beads 
and to read their code upon magnetic orientation an excitation light of 488 nm was used. To 
visualize the fluorescence in the cells at the surface of the microcarriers, excitation 
wavelengths of 567 nm and 647 nm were used. 
RESULTS & DISCUSSION
Immobilizing naked nucleic acids on the surface of encoded microcarriers
First, we characterized to which extent the surface of the digitally encoded 
microcarriers could become loaded with naked (and complexed) nucleic acids. We especially 
evaluated how the charge and charge density of the surface influences the loading of the 
nucleic acids. Figure 2 schematically shows the composition of the surface of the 
microcarriers used in this study. Note that the surface of the “naked beads” (being 
microcarriers without LbL coating) is negatively charged due to the presence of dissociated 
carboxyl groups. 
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Figure 2. Composition of the surface of the encoded microcarriers used in this study. (A) The so 
named “naked beads” have negative charges at their surface due to the presence of carboxyl groups. 
(B) ”PAH coated beads” are naked beads coated with the polycation PAH. (C) ”LbL coated beads” are 
naked beads coated with different polyelectrolyte layers, alternatively with the polycation PAH and 
the polyanion PSS. As indicated in the figure, the outer layer of the LbL coating was respectively PAH 
(to obtain a positively charged surface) or PSS (to obtain a negatively charged surface).
Figure 3 and 4 visually show to which extent red (TOTO3) labeled naked pDNA 
becomes immobilized on microcarriers with a different surface. One can clearly see that 
only limited amounts of pDNA adsorb on the negatively charged beads while a positively
charged (LbL coated) surface enhances the adsorption.
Figure 3. Red (TOTO3) labeled naked pDNA immobilized on microcarriers with a different surface. 
Merged green/red fluorescence images (top row) show the green fluorescence of the microcarriers 
(note that polystyrene microcarriers doped with a green fluorophore were used in this study); the 
red fluorescence image (bottom row) shows that naked pDNA becomes immobilized at the surface 
of the microcarriers. The beads in all the figures of this paper are approximately 40 µm in size.
LbL coated beads
(outer layer PSS)
Naked beads LbL coated beads
(outer layer PAH)
PAH coated beads
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Figure 4. Red fluorescence images of the microcarriers at a higher magnification than in Figure 3. 
The insert shows the corresponding transmission image. It shows that all the beads in the 
transmission image become well covered with pDNA. 
In Figure 5 the red fluorescence at the surface of the microcarriers was quantified. 
While only low levels of fluorescence were obtained in case of negatively charged 
microcarriers, as expected, a positive surface charge of the microcarriers significantly 
increases the measured fluorescence and thus improves the pDNA loading on the 
microcarrier surface. A positive outer layer clearly plays an important role for the efficiency 
of pDNA adsorption onto the surface of microcarriers. Additionally, Figure 6 also reveals 
that LbL coating of the beads seems to result in a more homogeneous loading of the beads 
with pDNA compared to microcarriers coated with a single PAH-layer (PAH coated beads). 
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BA
Figure 6. Red (TOTO3) labeled naked pDNA immobilized on respectively (A) PAH coated beads and 
(B) LbL coated beads (with PAH as outer layer). The scale bar represents 10 µm.
Similarly, Figure 7 shows the adsorption of naked red Cy5 labeled siRNA on 
microcarriers with a different surface. As observed for naked pDNA, only limited amounts of 
siRNA do adsorb to the negatively charged naked beads while a positively charged surface
clearly enhances the adsorption.
Figure 7. Red Cy5 labeled siRNA immobilized on microcarriers with a different surface. The merged 
red/green fluorescence image (top row) shows the green fluorescence of the polystyrene 
microcarriers. The red fluorescence image (bottom row) shows that siRNA becomes immobilized at 
the surface of the microcarriers.
Naked beads LbL coated beads
(outer layer PSS)
LbL coated beads
(outer layer PAH)
PAH coated beads
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Next, this was also confirmed by quantifying the red fluorescence (data not shown). 
However, similar as with pDNA, the adsorption of siRNA to the microcarrier surfaces is 
apparently not only dependent on the charge of the surface but also on the composition of 
the charged surface, as the LbL coated beads showed again a much more homogenous 
distribution pattern compared to PAH coated beads (Figure 7). Though, one should take 
care in relating the amount of red fluorescence signal at the surface to the amount of 
nucleic acids as the fluorescence signal may become also influenced by the chemical 
composition of the coating 40.
Immobilizing (non-viral) nucleic acid complexes on the surface of encoded microcarriers  
Figure 9, 10 and 11 show that polyplexes and lipoplexes become immobilized at the 
surface of the beads. In contrast to the loading with naked pDNA and naked siRNA, the 
loading of the beads with poly- and lipoplex occurs more heterogeneously, as evidenced 
from the punctuated red fluorescence on the surface of the beads 
Figure 9. Red (TOTO3) labeled pDNA containing polyplexes (based on PEI) immobilized on 
microcarriers with a different surface. The merged red/green fluorescence image (top row) shows 
the green fluorescence of the polystyrene microcarriers. The red fluorescence image (bottom row) 
shows that polyplexes become immobilized at the surface of the microcarriers.
Naked beads PAH coated beads LbL coated beads
(outer layer PSS)
LbL coated beads
(outer layer PAH)
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Figure 10. Red (TOTO3) labeled pDNA containing lipoplexes (based on DOTAP: DOPE) immobilized on 
microcarriers with a different surface. The merged green/red fluorescence image (top row) shows 
the green fluorescence of the polystyrene microcarriers. The red fluorescence image (bottom row) 
shows that the lipoplexes become immobilized at the surface of the microcarriers. 
Figure 11. Red (Cy5) labeled siRNA containing polyplexes (based on PbAE1) immobilized on 
microcarriers with a different surface. The merged green/red fluorescence image (top row) shows 
the green fluorescence of the polystyrene microcarriers. The red fluorescence image (bottom row) 
shows that the siRNA polyplexes become immobilized at the surface of the microcarriers. 
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PAH coated beads LbL coated beads
(outer layer PSS)
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(outer layer PAH)
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Figure 12 shows an image at higher amplification: it reveals the homogenous loading with 
naked siRNA in opposite to the more heterogeneous loading with siRNA polyplexes. 
         
Figure 12. Fluorescent images of green microcarriers with LbL coating, loaded with red (cy5) labeled 
siRNA, either complexed (A) or free (B). The scale bar represents 50 µm.
Reverse transfection of cells by naked pDNA immobilized at the surface of encoded 
microcarriers
To evaluate the transfection efficiency of the immobilized nucleic acids, cells were 
grown on surface of the microcarriers. Figure 13A shows transmission and fluorescence 
images of microcarriers covered with cells; naked pDNA, encoding for a red fluorescent 
protein, was adsorbed to the surface of the LbL coated beads. The cells did not become 
transfected as the fluorescence image in Figure 13A did not show any red fluorescence in 
the cells. We hypothesize that a (too) strong binding of the naked pDNA to the surface of 
microcarriers may prevent the pDNA molecules to be released from the carriers surface and 
thus cellular internalization. The failure in the reverse transfection may be also attributed to 
the fact that negatively charged naked pDNA has difficulties in entering cells, due to 
negative charges at the cell membrane.
Reverse transfection of cells by complexed pDNA and siRNA immobilized at the surface of 
encoded microcarriers
Further we investigated whether cells grown on the beads could become reversely 
transfected with siRNA and pDNA complexes present at the surface of the beads. Segura et 
Naked siRNA on LBL coated beadsComplex siRNA on LbL coated beads
EVALUATION OF DIGITALLY ENCODED LAYER-BY-LAYER COATED MICROPARTICLES FOR REVERSE TRANSFECTION– CHAPTER 4
99
al indeed showed that nucleic acid complexes immobilized on flat surface, could deliver the 
nucleic acids into cells 15,16,20. Our group showed recently that (small, positively charged) 
PbAE1 based siRNA complexes were able to induce efficient siRNA-mediated gene silencing 
in cells grown in wells of microtiterplates, without causing significant cytotoxicity 37. As cells 
immobilized at the surface of microcarriers start to overgrow each other after a number of 
days, siRNA release from the coating of the microcarriers into the cells should occur fast 
enough. Therefore we preferred to work with PbAE1:siRNA complexes as PbAE1 
(bio)degrades relatively fast which may facilitate in time the release of the PbAE1:siRNA 
complexes from the coatings into the cells. The results showed that PbAE1:siRNA 
compelexes loaded on the surface of the beads were not able to induce efficient down 
regulation in cells, grown on microcarriers (Fig. 13B).
Similarly as for the PbAE1:siRNA complexes, significant transfection of the cells on 
the microcarriers did not occur when pDNA polyplexes, based on PEI, were loaded at the 
surface of the microcarriers (only a low level of gene expression could be observed; data not 
shown).
  A         B
                    
Figure 13. (A)Transmission (top row) and merged red/green fluorescence images (bottom row) of 
Vero cells grown at the surface of LbL coated beads (PAH as outer layer) loaded with TOTO3 labeled 
pDNA encoding for a red fluorescent protein. Clearly, the cells do not express the red protein.
(B) HuH-7_eGFPLuc cells grown at the surface of LbL coated beads loaded with PbAE1:siRNA 
complexes. siRNA were not able to induce efficient down regulation in cells as the cells are  
express the green protein. The scale bar represents 10 µm.
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Reverse transduction of cells by adenoviral vectors immobilized at the surface of encoded 
microcarriers 
Subsequently we investigated whether adenoviral vectors (bearing the genetic code 
for GFP or RFP) immobilized in the LbL coating surrounding the beads could transduce the 
cells grown on the surface of the beads. Recently, bioactive adenoviral vectors embedded in 
multilayered polyelectrolyte films on a flat surface were shown to efficiently transfect 
different cell lines 29. Also Fischlechner et al. suggested virus coating of LbL coated colloids 
41,42 and introduced these materials for use in multiplex suspension arrays to detect virus 
specific antibodies 43. Hobson D.A et al proposed to use the extremely tight interaction 
between streptavidin and biotin to immobilize adenoviral vectors on the surface of wells 
and microparticles 18,19.
As Figure 14 shows, after 24 h a large percentage of cells that had settled onto the 
virus-coated microcarriers expressed RFP and thus became transduced. Importantly, only 
the cells attached to the surface of the beads became transduced (and not the cells being 
present in between the beads), as one can see when comparing the transmission and 
fluorescence images in Figure 15. It proves that the adenoviral particles did not detach from 
the microcarrier’s surface during the time of the experiment, which would have resulted in 
(unwanted) transduction of the free cells. 
A B C D
Figure 14. (A-C) Transmission (top) and merged red/green fluorescence (bottom) images of Ad-RFP 
coated microcarriers loaded with Vero-1 cells. In (D) microcarriers were used which did not contain 
viral particles in their coating (negative control). The scale bar represents 10 µm.
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A B
Figure 15. (A) Transmission and (B) merged green/red fluorescence images of a dispersion 
containing respectively Ad-RFP coated microcarriers loaded with Vero-1 cells and “free Vero-1 cells”. 
The scale bar represents 50 µm. 
One could argue, however, that the cells on the microcarriers became transducted 
by adenoviral vectors remaining free in the solution between the microcarriers in stead of 
by viral particles immobilized at the surface of the microcarriers. Therefore we performed 
transduction experiments on Vero-1 cells grown in 96 well plates using the “wash water”
obtained in the preparation of the adenoviral coated microcarriers, thus containing the free 
adenoviral particles which did not become incorporated in the LbL surface. Clearly, washing 
the viral coated beads three times is sufficient to remove all free adenoviral particles as this 
solution did not transfect cells anymore (see fig 16). Note that the Ad-RFP loaded beads 
used in Figure 14 were washed three times and that the transduction of the cells on the 
beads could therefore only arrive from Ad-RFP particles immobilized in the coating of the 
beads (as there were no viral particles remaining in the surrounding solvent). The code in 
the microcarriers allows to identify with which viral-constructs the cells became transduced, 
and thus allows to know which protein target is expressed in the cells on a specific 
microcarrier. This approach may become interesting for making cell-based expression arrays 
with promises for proteomics and drug discovery. 
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A B C D
Figure 16. Transmission (top) and red fluorescence (bottom) images of Vero-1 cells seeded in 96 well 
plates transfected with respectively (A) the virus dispersion used to coat the microcarriers and (B) 
the first, (C) the second and (D) the third wash water as obtained during the preparation of the Ad-
RFP coated microcarriers 
CONCLUSION
In this chapter we showed that LbL coated encoded beads are suitable to immobilize 
respectively viral vectors, naked nucleic acids and complexed nucleic acids. However, naked 
nucleic acids and non-viral nucleic acid complexes immobilized in the LbL coatings at the 
surface of the beads did not (significantly) transfect the cells that grow on top of the LbL 
coated microcarriers. Highly likely this is due to the limited release of the naked and 
complexed nucleic acids from the microcarrier’s surface. However, adenoviral particles 
immobilized in the LbL coating were able to selectively tranduce the cells that were grow on 
top of the “adenovirus coating”. Indeed, we showed that adenoviral particles immobilized in 
the polyelectrolyte layer retained their ability to infect cells. Importantly, only the cells at 
the surface of the microcarriers, thereby in close contact with the adenoviral particles, 
became transduced, while free cells (i.e. cells present in the dispersion but not attached to a 
microcarrier) were not transduced. In conclusion, LbL coated encoded microcarriers may 
become a valuable tool to use in cell based microarrays in which the cells have to become 
transfected with nucleic acids. However, an optimal way should be found for appropriately 
immobilizing the nucleic acids at the surface of the microcarriers: on the one hand the 
binding should be strong enough in order to avoid the release into the surroundings of the 
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microcarriers, a too strong binding on the other hand may prevent that the nucleic acids 
become taken up by the cells. 
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ABSTRACT
Counterfeiting of drugs is a real threat to public health in both developing and 
industrialized countries due to the high risk and inevitable occurrence of patients taking, or 
being treated with drugs of inferior quality. “In-drug labeling”, i.e. the safe labeling of the 
drug instead of the packaging, would be a major step forward to combat counterfeiters. The 
digitally encoded microparticles described in this paper, called Memobeads, may become a 
major tool in combating counterfeiters of pharmaceuticals who are becoming increasingly 
sophisticated. Here we show that Memobeads can be incorporated in drug tablets, by far 
the most widely used drug dosage form in the world. We found that entrapping the 
Memobeads in starch-based granules protects them from deformation during tabletting, 
even when high compression forces are applied. 
Compared to other types of encoded microcarriers, Memobeads have a number of 
assets for “in-tablet” labeling. One asset being that ingested Memobeads are highly unlikely 
to be toxic to humans; another asset being that the number of unique Memobeads is 
virtually unlimited, an obvious advantage considering the huge number of pharmaceuticals 
at risk of being counterfeited.
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Chapter 5
Turning to Digitally Encoded Drug Tablets 
to Combat Counterfeiting
INTRODUCTION
Pharmaceutical products are an important part of the healthcare system. Therefore,
drug counterfeiting can cause a wide array of serious medical and economic damages. 
Although the problem is recognized by official health organizations like FDA and WHO, 
actions taken so far to combat drug counterfeiting have been insufficient 1-4. There are 
different types of counterfeit drugs that can affect the patient. The counterfeit products look 
identical to the legitimate ones, and may either lack the active ingredient, contain active 
ingredients different from those listed on the label, be diluted and/or contain harmful 
impurities. Other counterfeit drugs are intentionally mislabeled to extend the expiration 
date 5. 
Various researchers estimate different percentage of counterfeit medications in total 
pharmaceutical market. The World Health Organisation (WHO) has estimated that 10% of 
global medicines are counterfeit 3. But because of the incomplete database on counterfeit 
drug, it is hard to estimate the true extent of the problem and the real level could be higher 6
.In parts of Africa and Asia this figure exceeds 50% 7. The 192,000 patients killed by fake 
drugs in China in 2001 or the 3000 died people in Nigeria in 1995 because of fake vaccines 
gives an indication of the scale of human suffering 8,9. 
With increasing free trade policies and the new phenomenon of purchasing drugs 
from online pharmacies, counterfeit drugs are becoming widespread. In some cases, internet 
pharmacies sell products of unknown quality 10. Only 12% of e-pharmacies displayed quality 
accreditation seals 11,12. Today drug counterfeiting is a global problem and it is not limited to 
developing countries 4. Generally in developing countries, life-saving medications such as 
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antibiotics, painkillers and vaccines are being counterfeited and distributed via the local 
market. In industrialized countries the counterfeiters generally target “lifestyle drugs” such 
as hormones and anti-psychotics via the internet 13-16. The problem is growing and there is 
no simple solution or a single "magic bullet" technology to combat counterfeiting. To solve 
this major world wide problem coordinated action between governments, law enforcement 
agencies, health professionals, the pharmaceutical manufacturers, wholesalers and patients 
is required 17-19. The WHO has issued several guidelines against counterfeiting 20-24. Currently 
there are a number of anti-counterfeiting technologies for pharmaceuticals available or 
under development. These technologies range from the very simple and low cost to highly 
sophisticated and expensive ones. To obtain higher security, a combination of technologies 
can be used. Strategies differ by products and pharmaceutical manufacturers should choose 
the most effective strategy based on different parameters for each product.
Anti-counterfeiting technologies 
Anti-counterfeiting technologies basically can be applied on two different levels: the 
package and the product. In packaging-based measures, the security device is used on 
packaging, whereas the second approach is focused on labeling of the dosage form. Using 
anti-counterfeiting technology at the level of dosage form is useful even when the products 
are separated from their package. The product labeling could be visible, which is called “on 
product” marking or applied inside the product (invisible), named “in product” labeling. Anti-
counterfeiting technologies can also be classified into “overt”, “covert” and “forensic” 
technologies 25. Each of them is effective to some extent as a counterfeit-proof.
(a) Overt features: these security features on product or packaging, e.g. holograms, 
color shifting inks and watermarks, are apparent and visible; they require inexpensive 
instruments for reading out the information but are easily mimicked 26. Evidence shows that 
visible security features or coding are not sufficient to protect products from counterfeiting. 
Using some kind of colour which makes the feature more difficult to reproduce or combine 
an overt design with a covert one can add extra security to this technique. 
A new technique offers security microstructures that can be created by electron 
beam lithography (EBL) 27. On-product marking is also an overt technology which allows 
placing special images or codes on oral dosage form. Colorcon has developed a new on-
TURNING TO DIGITALLY ENCODED DRUG TABLETS TO COMBAT COUNTERFEITING-CHAPTER 5
111
tablet marking technique. With this technique the desired image or code is written upon the
tablet surface by laser light 28.
Merck KGaA manufactures pearlescent pigments to use in hard and soft gelatin 
capsules and in film-coated tablets. These pigments can be distinguished by their 
characteristic shape, color and pearlescent effect and makes counterfeiting more difficult. 
The pigments consist of titanium oxide (E171), iron oxide (E172) and potassium silicate 
(E555) known as “mica” being widely approved food and pharmaceutical colorants (brand 
name Candurin® pigments) 29,30.
(b) Covert features or hidden markers on the product packaging (like certain inks and 
dyes that fluoresce or absorb ultraviolet light, invisible bar codes) are not visible to the eye 
and require simple equipment, such as an UV lamp for identification 31-33. Recently, a
technology has been developed which can print invisible micro-points in the packaging 
design. Detection of this micro-point in all print structure of packaging is based on a reader 
and special software 34,35. Microtags are other covert devices which can be applied to 
packaging components. They can include multivariate levels of information. These microtags 
with the size about 75 microns also can be precisely engineered for forensic 
authentication36.
(c) Forensic (or well hidden) markers can be based on a diversity of technologies, 
such as chemicals, biologicals or DNA taggants, that can be added on the packaging label or 
even into the drug itself. These markers are much more difficult to reproduce and expensive 
to read, because sophisticated analytical instrumentation is required 26. Compared to the 
other methods, DNA (or other nucleic acid) taggants seems to be most effective as a 
counterfeit-proof. This technology involves the inclusion of a DNA marker into the product 
label or on the product surface. Applied DNA Sciences (APDN) provides patented DNA-based 
technologies to prevent and identify counterfeits. According to the company the patented 
technology, SigNature, can be used on almost any consumer product. A primary test can be
performed using a detection pen, which will cause a color change if the SigNature ink is 
present 37. Also another company, DNA Technologies (Australia) Pty Ltd, has a patent for 
DNA taggants, called DNA Matrix™ 38.
To combat counterfeiting and to allow tracking and tracing a drug throughout the 
supply chain, the packaging of an increasing number of drugs, such as Viagra®, is being 
“protected” by radio frequency tags (RFID), barcodes and/or serialization 32,39-41.
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Unfortunately, such tracking and tracing technologies are only effective if the drugs are not 
repackaged. However, manufacturers often do not ship drugs directly to hospitals and 
dispensing pharmacies. For example, drugs are often sold to wholesalers or to repackagers 
who move drugs from bulk to unit-of-use containers. These multiple transactions can 
provide a means for counterfeit drugs to enter the legitimate drug supply chain. To 
overcome this, “in-drug labeling”, i.e. the labeling of the dosage form (tablet, capsule, 
cream, solution…) itself instead of the packaging of the drug could help to combat 
counterfeiters. 
Incorporation of taggants or chemical markers in the drugs themselves is much less 
developed and, to our knowledge, not yet used. A major reason is clearly that in-drug 
labeling requires both extensive toxicological screening of the taggant as well as formulation 
compatibility testing. So far only a very limited number of taggants have been proposed for 
in-product labeling of pharmaceuticals. For example, color-coded particles (5 – 45 µm) which 
are regarded as food safe (available under the brand name SECUTAG®). The basis of the 
SECUTAG® is melamine alkyd polymer particles. The code is produced by the use of sandwich 
method, in which 4-10 variably coloured layers are stratified. The identification of the colour
code needs a microscope or an automatic reader 42. ARmark™ covert markers are another 
authentication technology system developed by Adhesives Research Inc. for in-product 
labeling. The markers created by using nanoentonography are identified via digital micro-
imaging hardware and customized software programs 43.
There is no guarantee of avoiding counterfeiting when the security device is just on 
the packaging. In this chapter we are launching a new concept for the in-product labeling of 
tablets, by far the most widely used drug dosage form in the world. We recommend digitally 
encoded micro-particles, known as Memobeads, for this purpose. Memobeads are micron-
sized fluorescent polystyrene beads which are graphically encoded by “spatial selective 
photobleaching” of the fluorescence 44,45. In this study we evaluate (a) how Memobeads can 
be incorporated into tablets and (b) whether the digital code withstands the compression 
forces applied during tabletting. We also critically discuss the toxicological aspects of orally 
administered Memobeads.
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MATERIALS & METHODS
Memobeads
Surface carboxylated polystyrene beads of 39 µm (Sperotech, Libertyville, USA), dyed 
with a fluorophore were graphically encoded by “spatial selective photobleaching” of the 
fluorescence 44,45. Photobleaching is a photo-induced process by which fluorescent 
molecules lose their fluorescent properties, which results in fading of the fluorescent colour. 
By using a specially adapted laser scanning confocal microscope, patterns can be 
photobleached at any depth inside the fluorescently dyed microsphere. Any geometry can 
be bleached, such as a symbol, an alphanumeric code, a barcode and even a logo. Details on 
the encoding procedure can be found elsewhere 46. Certainly, as beads move and rotate, for 
the code to be clearly visible the beads need to be properly positioned at the time of 
decoding. We have shown previously that by providing the microspheres with orientation 
information, such as a (permanent) magnetic moment, it is possible to automatically 
position the spheres correctly for readout. For this purpose, as schematically shown in 
Figures 1C and 1D, ferromagnetic chromium dioxide particles were incorporated in the 
surface of the beads by the so called Layer-by-Layer (LbL) technology. 
Layer-by-Layer (LbL) technology is based on the alternate adsorption of oppositely 
charged polyelectrolytes/nanoparticles onto a charged substrate. The LbL layer in this study 
was build with poly(allylamine hydrochloride) (PAH) as polycation and poly(styrene
sulfonate) (PSS) as polyanion. The surface carboxylated microspheres (negatively charged) 
were therefore suspended in 1 ml PAH solution (2 mg/mL in 0.5M NaCl); the suspension was 
continuously vortexed (1000 rpm, 25°C) for 15 min. The non-adsorbed PAH was removed by 
repeated centrifugation (30 sec at 1500 rcf) and washing (with deionized water). 
Subsequently, the microspheres were dispersed in deionized water containing the negatively 
charged chromium dioxide nanoparticles (CrO2 NP, 375 nm average diameters). The 
dispersion was continuously shaken for 15 min and the excess of CrO2 NPwas removed by 
repeated centrifugation/washing steps. The microspheres were further coated with 4 layers 
in the following order: PAH / PSS / PAH / PSS. These LbL coated microspheres were 
resuspended in 1 ml of deionized water and subsequently encoded (as described above) and 
magnetized. These beads are magnetized in a strong magnet at the time of encoding. For 
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decoding, the beads are subjected to a weak magnetic field, thereby orienting the beads in a 
perfect position for reading out the code 47.
Production of a pharmaceutical formulation containing the encoded beads
Layering of encoded beads on non-pareil seeds. Microcrystalline cellulose spheres were 
used as non-pareil seeds (300 g of Cellets® 700 (700-1000 µm) (Pharmatrans, Basel, 
Switzerland)). Layering was performed in a fluid-bed apparatus (GPCG 1, Glatt, Binzen, 
Germany) used in the bottom spray mode with the Wurster setup (nozzle diameter 0.8 mm; 
spray rate of 4.6 g/min for 25 min; atomising pressure 1.5 bar; product temperature 45°C). 
The layering solutions were prepared by dissolving first a binder and then suspending the 
encoded beads in demineralised water. As binder, polyvinylpyrolidone (PVP, Kollidon® 25, 
BASF, Ludwigshafen, Germany) (1%, w/w) or hydroxypropylmethylcellulose (HPMC, Opadry®, 
Colorcon, Dartford, UK) (9%, w/w) were used. The content of the encoded beads in the 
layering solution was adjusted to obtain a yield of 8 beads/pellet after layering. The layering 
solution was stirred manually during the process. Before layering, the pellets were 
preheated until a product temperature of 45°C was reached.
Encoded tablets produced by granulation and compression. Hydroxypropylmethylcellulose 
(Methocel® E15 LV, Colorcon, Dartford, UK) and UNI-PURE® EX starch (National Starch and 
Chemical Company, New Jersey, US)) were mixed for 15 min in a Turbula mixer (model T2A, 
W.A. Bachofen, Basel, Switzerland). The HPMC and starch concentration in the powder 
mixture was 7 and 93% (w/w, dry mass), respectively. The powder mixture was granulated 
for 10 min at 60 rpm by means of a planetary mixer (Kenwood Chef, Hampshire, UK) with 
demineralised water (40 %, w/w, wet mass) in which encoded beads were suspended. 
Subsequently the wet mass was put through a sieve (0.94 mm) and then the granules were 
dried in the oven for 12 h at 40°C. The dry granules were sifted and the fraction between 
250 and 710µm was further blended with 0.5% (w/w) magnesium stearate (< 90 µm) (BUFA, 
Brussels, Belgium) in a Turbula mixer for 1 min. With these obtained granules tablets (500 
mg) were then prepared using an eccentric compression machine (Korsch EKO, Berlin, 
Germany) equipped with a flat faced double punch of 12 mm at compression forces ranging 
from 53 to 178 MPa. 
Encoded tablets produced by direct compression. A suspension of Memobeads was dried in 
the oven for 12 h at 40 °C to obtain a solid sample. To destroy the aggregate of the beads, 
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dry sample was first shacked in a Turbula mixer with glass beads. This powder was gradually 
mixed with 250 g α-lactose monohydrate (Tablettose®, Meggle, Wasserburg, Germany) in a 
Turbula mixer for 30 min. The mixture was blended with 0.5% (w/w) magnesium stearate for 
another 1 min. Afterwards tablets (500 mg) were prepared using the compression machine 
described above at compression forces ranging from 53 to 223 MPa.
Recovering the Memobeads from the tablets and decoding. The Memobeads were 
recovered from a tablet (500 mg) by dissolving a part (about 50 mg) of a tablet in 500 µL 
distilled water. After centrifugation, the supernatant containing dissolved materials was 
removed. 100 µL of distilled water was added to the undissolved material containing beads. 
The sample was vortexed and applied on a microscope slide and imaged by a confocal laser 
scanning microscope (model MRC1024 UV, BioRad, Hemel Hempstead, UK) equipped with a 
water immersion objective lens (Plan Apo 60x, NA 1.2, Nikon). The 488 nm line of a krypton-
argon laser was used for excitation. Note that a weak magnetic field was applied to the 
microscope table to allow perfect positioning of the Memobeads for readout (see above).
Cell toxicity of Memobeads 
The cell toxicity of the Memobeads was evaluated by the EZ4U assay (Biomedica 
GmbH, Vienna, Austria) 48. A large amount of LbL coated microcarriers (> 106) was dispersed 
for 48, 72 and 140 h in cell culture. In this way, compounds that are possibly present in the 
LbL coating and the polystyrene core of the microcarriers, and which may be toxic to cells, 
were “extracted” in the cell culture medium. Cells were subsequently grown in the cell 
culture medium obtained in this manner. An EZ4U test was performed after 48, 72 and 140 h 
(in the exponential phase of growth). Briefly, 50 µl of EZ4U substrate, together with 450 µl 
culture medium, was added to each well and incubated for 2-5 h. The absorbance was 
measured with a Wallac Victor2 absorbance plate reader (Perkin Elmer; Waltham, MA) set at 
450 nm with a reference wavelength of 620 nm. Negative and positive control experiments 
were included by using cell culture medium that had not been exposed to Memobeads and 
by using cell culture medium that was supplemented with 10 mg/ml of phenol, respectively. 
Release of chrome (Cr) and fluorophore from Memobeads suspended in gastric fluid
An amount of Memobeads (approximately 10/ml and 50000/ml in the determination 
of the release of Cr and fluorophore, respectively) was suspended in 200 ml simulated 
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gastric fluid 49 for 2 h at 37°C. Subsequently, the Memobeads were transferred into 200 ml 
simulated intestinal fluid for 3 h at 37°C. The dispersions were continuously shaken. The Cr 
concentration in the supernatant was determined by Hidrocontrol (Antwerpen, Belgium). 
The fluorescence of the supernatant was measured by the highly sensitive detector of a 
Fluorescence Correlation Spectroscopy (FCS) instrument which can even measure single 
fluorophores and which is considered to be a highly sensitive fluorimeter 50,51.
RESULTS
Memobeads digitally encoded with drug information 
As shown in Figure 1A, barcodes but also information like the name of the drug, the 
name of the producer, the batch number, the expiration date, can be clearly written inside 
homogeneously fluorescently dyed microspheres of 39 µm by “spatial selective 
photobleaching” (i.e. photobleaching of certain regions). 
PSS
PSS
A
B
C D
Figure 1: Composition of a Memobead. (A and B) Confocal images of the middle plane of encoded (39 
µm diameter) Memobeads; the scale bar is 20 µm. (C) Schematic presentations of “dot-encoded” 
(top) and “bar-encoded” (bottom) Memobeads; the surface of the Memobeads contains 
ferromagnetic CrO2 nanoparticles and polyelectrolytes. (D) The coating is obtained by sequential 
adsorption of poly(allylaminehydrochloride) (PAH), CrO2, PAH, poly(styrenesulfonate) (PSS), PAH and 
PSS at the surface of the Memobeads by Layer-by-Layer (LbL) technology 52. The ferromagnetic 
properties allow orienting the beads correctly to make the code clearly visible at the time of 
decoding 46.
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Note that the information is written in (the middle plane of) the beads, as illustrated 
in Figure 2. Because the pattern in the carriers is bleached by a scanning laser beam “pixel by 
pixel” and “line by line”, the time needed for writing the code depends on the complexity of 
the pattern.  Therefore Memobeads with a simple one-dimensional “dot code” (see Fig. 1C), 
which requires only a single line-scan, were used in the experiments of this study.
    
Figure 2: Confocal optical sections of a Memobead. The code is written in the central plane of the 
Memobead. At that position (0 µm) the code is clearly visible. At another depth in the Memobead
(i.e. above (> 0 µm) or below (< 0 µm) the encoded central plane) the code becomes unreadable. The 
code is truly “hidden” inside the Memobead and can only be revealed by a confocal microscope 
focused at exactly the right depth inside the Memobead. The scale bar is 20µm.
Encoding pellets and tablets with Memobeads
Drugs can be formulated in pellets which subsequently can be filled in capsules. To 
produce encoded pellets we started layering of pellets with beads. Figure 3 is an image of an 
encoded microcarrier layered on a pellet, prior to isolation and decoding of the microcarrier.
We studied the influence of different parameters on layering of pellets with the 
encoded microcarriers. Based on our results layering with smaller beads have better 
efficiency (10µm better than 40µm (data not shown). Shear stress at different drying time 
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has no strong influence on layering of pellet (Fig. 4). Comparing different way of drying (in 
oven and fluid-bed) shows that by drying in oven we lose fewer beads, layered on the pellets 
(Fig 5A). The encoded beads layered on the pellets could easily be recovered and 
demonstrated their code to be intact (Fig 5B). However, a lot of encoded beads are lost 
during processing and the layering of pellets with encoded beads has low efficiency. These 
experiments proved that the product labelling by encoded microcarrier layered on the 
pellets is possible but not efficient. Therefore we focused further on using encoded 
microcarrier inside of the granules for in product labelling of tablets, the most widely used 
pharmaceutical formulation.
Figure 3. (A) A pellet with HPMC layer around it. (B, C) 10µm fluorescent bead on pellet
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Figure 5. (A) The number of beads in different way of drying. (B)Dot-encoded beads recovered from 
pellet. 
The production of tablets in pharmaceutical industry is mainly via direct compression 
of a drug/excipient powder mixture. This method is rather simple and has became popular in 
recent years as it saves time, labor, requires neither heat nor moisture, and all this may 
actually enhance the stability of the drug. Figure 6 shows Memobeads recovered from 
tablets produced by direct compression under different compression forces. Clearly, only at 
low compression forces the dot code does not deform; high compression forces destroy the 
code.
Figure 6: Dot-encoded beads as obtained from tablets made by direct compression of the powder 
mixture. The compression forces used during tabletting are indicated on the images. The 
Memobeads do not survive a compression force of 178 MPa as the code is no longer visible. The 
scale bar is 10 µm.
In order to enhance flow characteristics of the powder, avoid segregation of 
compounds, enhance compression behaviour and avoid dust generation, powder particles 
are often “granulated” before further compression. During this agglomeration process 
irregular-shaped granules (approximately 200-1000µm in size) are formed, containing drug 
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and other excipients (Fig. 7A). Figure 7B shows a (non confocal) fluorescence image of a part 
of a HPMC/starch-based granule that contains three (fluorescent) Memobeads; note that, 
because a non-confocal fluorescence microscope was used, the codes in the beads are not 
visible. Figure 7C shows confocal images of dot-encoded Memobeads which were isolated 
from tablets made by compression of the HPMC/starch granules. Clearly, the Memobeads 
remain spherical and, especially, the dot code does not deform and remains perfectly 
readable. 
Figure 7: Dot-encoded beads as obtained from tablets made by compression of HPMC/starch 
granules. (A) Schematic presentation of the compression of granules (yellow, left image) into a tablet 
(right image); the granules and therefore the tablets contain encoded Memobeads (green). (B) Image 
obtained with an epifluorescence microscope of a part of an HPMC/starch granule (diameter about 
0.5mm) in which three (fluorescent) Memobeads can be seen. (C, D) Confocal image of dot-encoded 
Memobeads obtained from the tablets (compression force used was 178 MPa). The scale bar is 10
µm.
More importantly, even when the granules were compressed at higher compression 
forces (up to 178 MPa), the dot codes in the Memobeads survived. One should note that the 
beads also remained perfectly capable of orientation by the magnetic field (a requirement 
for being able to see the code in the beads). This indicates that the chromium dioxide 
nanoparticles in the surface of the Memobeads (Fig. 1C) are not relocating by the high 
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compression forces. This is not surprising since they are strongly bound by electrostatic 
interactions with the polyanions and polycations of the LbL coating (Fig. 1D). Indeed, 
changing the positions of the nanoparticles would result in another orientation of the beads 
when brought into the magnetic field at the time of readout. Also note that, compared to 
two-dimensional codes, dot codes could be considered as the most “sensitive” towards 
deformation as deforming a small region in the microspheres would probably make the code 
unreadable. 
As described above, the dot code withstands higher compression forces in case 
where the Memobeads are first embedded in a granule (Fig. 7C). It seems that the 
HPMC/starch matrix of the granules (Fig. 7B) physically protects the polystyrene matrix of 
the Memobeads from deformation by the high forces. 
Uptake by the gut of orally ingested Memobeads 
Memobeads in the tablets will be orally ingested by the patients. Obviously, the 
question arises whether Memobeads are harmful to humans. “Memobead related toxicity” 
could be due to (a) accumulation of the beads into the tissues after absorption by the 
digestive track and (b) compounds (like fluorescent dye, chromium, chromium dioxide 
particles, styrene mono- and oligomers, polyelectrolytes; see Fig. 1C) released from the 
Memobeads while they are present in the gastric and intestinal fluids. When debating the 
toxicity of Memobeads in the tablets it is important to keep the following in mind. As the 
Memobeads have no pharmacological or adjuvant function and are only intended for 
counterfeiting detection, the daily intake of Memobeads will be very limited. Assuming the 
presence of 10 Memobeads per tablet and further assuming one takes 10 tablets a day, it is 
reasonable to say that the total number of Memobeads administered per day will about one 
hundred. Note that the total mass of 100 Memobeads is estimated to be only about 3 µg. 
Let us now consider the extent Memobeads are expected to be adsorbed by the gut. 
The lining of the gut is designed for the absorption of ions/molecules (nutrients) with a 
molecular mass of less than about one thousand 53; it is essentially impermeable to 
particulate matter. However, a limited amount of particulate material can be transported 
across the intestinal barrier. Some interesting information is available on this topic  
particularly from  pharmaceutical research, as gastrointestinal absorption of nano- and 
microparticles is very well understood, allowing the oral delivery of vaccines, peptides and 
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proteins. Indeed, membranous (M) cells (like in the domes of the Peyer’s patches) are well 
known to be endocytotic allowing them to take up bacteria and very small particles. 
Although the uptake of bacteria and bacteria-sized particles by the M cells is well 
documented 54, little is known about the uptake of larger particles. Eldridge et al found that 
orally administered biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres with a 
diameter of 10 microns or larger did not become absorbed by the gut walls, whereas 
microspheres smaller than 10 microns were specifically taken up into the Peyer’s patches. 
Microspheres between 5-10 microns in diameter remained fixed in the patches for an 
extended period (up to 35 days), while microspheres smaller than 5 microns were 
disseminated within macrophages to the mesenteric lymph nodes, the blood circulation and 
the spleen 55. Studies on polystyrene and PLGA particles, both in cell culture and in animals 
in vivo, have shown that particle uptake decreases with particle size. M-cells may take up 
particles up to 10 µm in size 56,57, while particles up to 2 µm have been reported to be taken 
up by absorptive enterocytes 58. LeFevre et al. administered 6 µm and 16 µm polystyrene 
microspheres orally to mice. They found that the larger particles did not accumulate in 
intestinal Peyer’s patches, mesenteric lymph nodes, or other organs of the 
reticuloendothelial system or in the blood, even after the maximum dosage of millions of 
particles per day for 60 days. However, under similar administration the smaller particles 
were found in Peyer’s patches, mesenteric lymph nodes, and lungs 59. 
Not only size but also surface properties determine the susceptibility for uptake of 
particles by M cells: hydrophilic particles are known to adhere less to M-cells than 
hydrophobic ones 60 and since the intestinal surface is negatively charged 61, positively 
charged particles are expected to interact more with the cells than neutral or negatively 
charged particles. 
Based on the observations above it is reasonable to assume that particles larger than 
about 10 µm, like Memobeads which are around 40 µm in size, are not taken up by the gut. 
We also note that, even if larger Memobeads were preferred they could be easily obtained 
by the same encoding/decoding approach. 
Toxicity of the ingredients released from Memobeads
Let us further consider to what extent Memobeads are expected to release foreign 
compounds in the gastrointestinal fluids which could become absorbed by the gut. 
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In mass production, polystyrene is the major component of the Memobeads. 
Polystyrene is very often used for food packaging and is considered to be non- toxic as it is 
insoluble in body fluids. Polystyrene is, however, often contaminated with styrene 
monomers which are of potential concern 62. The lethal oral dose (LD50) for styrene 
monomers is about 5 g/kg in rats 63. The WHO guideline for styrene monomers in drinking 
water is 20 µg/l 62. Assuming 100 beads are ingested daily (having a total mass of about 3 µg) 
it is reasonable to assume that the daily absorption of styrene monomers from Memobeads 
will be orders of a much lower magnitude than the daily absorption of styrene monomers 
tolerated when drinking water. 
The surface of the Memobeads contains ferromagnetic chromium dioxide nano-
particles (Fig. 1C) which could be released from the beads once they are in the 
gastrointestinal fluids. Clearly, this is highly unlikely as they are tightly bound in the coating 
of the Memobeads (see above). Chromium dioxide is insoluble in water and organic solvents 
and may thus be regarded as essentially non toxic. The oral LD50 in rats for chromium (II) 
chloride and chromium acetate hydrate are 1.870 and 11.260 mg/kg, respectively 64. 
Chromium is normally found in water at concentrations less than 2 µg/L and no more than 
50 µg/L is allowed in drinking water 65. We determined the amount of chromium released 
from Memobeads after being dispersed for 2 h in simulated gastric fluid and subsequently 3 
h in simulated intestinal fluid. Typically, the chromium concentration remained below 10 
µg/L (Fig 8); note that in these experiments approximately 2000 Memobeads were 
suspended in 200 ml fluid which is much higher than the number of Memobeads we expect 
a patient will take per day. 
As shown in Figure 1C, the chromium dioxide nanoparticles are adhered to the 
surface by a layer of polyelectrolytes. Clearly, both PAH and PSS are only present in trace 
amounts (far less than 1 % w/w). Toxicological data are not available for either PAH or for 
PSS. However, even in the unlikely event that PSS and PAH were released from the 
Memobeads in the gastrointestinal fluids the absorption of PAH and PSS by the gut is 
expected to be negligible as they are both high molecular weight compounds. One should 
also note that poly(styrenesulphonate) is even administered orally for the treatment of 
hyperkalaemia and PAH appears promising as phosphate binder to treat 
hyperphosphataemia among chronic renal failure and dialysis patients 66,67.
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Figure 8. Release of Cr from encoded beads at different condition
Memobeads are loaded with a fluorophore. By fluorescence recovery after 
photobleaching 68 we found that >70% of the fluorophores is completely immobilized in the 
polystyrene matrix 69. Such a large immobile fraction is indeed a prerequisite for being able 
to write a permanent code. Since only a small fraction of the fluorophores is (very slowly) 
mobile, we do not expect a significant leaking of fluorescent molecules out of the 
Memobeads into the environment. Indeed, we observed that the fluorescence of 200 ml 
gastric/intestinal fluid in which 50,000 Memobeads per ml were suspended for 5 h remained 
as low as the fluorescence of the blank sample (data not shown; the fluorescence of the 
supernatant was measured by the highly sensitive detector of a Fluorescence Correlation 
Spectroscopy instrument which can even measure single fluorophores) 70.The cytotoxicity of 
the Memobeads was also screened on A549 and Vero-1 cells. Therefore, as described in the 
materials and methods section, a monolayer of cells was cultured in a “Memobead extract” 
and the cytotoxicity of the medium was evaluated. As shown in chapter 3, the cells survived 
well indicating that Memobeads do not release compounds that are toxic to cells. 
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DISCUSSION
One can raise the question why Memobeads are better suited for the in-product 
labeling of tablets compared to other kinds of optically- or graphically-encoded microcarriers 
as reviewed by Braeckmans et al. 45. As shown in Figure 8, in “colloidal encoding” of 
microcarriers two type of beads are used 71,72: (a) large “support” beads (approximately 100 
µm in size) and (b) smaller (fluorescent) silica “encoding” beads (0.2 – 5 µm in diameter). A 
fluorescent code is generated on each support bead through the physical attachment of 50 
to 400 encoding beads, which contain specific combinations of fluorescent dyes. Although, 
numerous uniquely encoded beads can be generated in this way, colloidal-encoded 
microcarriers are very likely unsuitable for in-product tagging of tablets as there is a real risk 
that the small encoding beads will be absorbed by the gut. 
Figure 8. Colloidal encoding. (Left) Fluorescence microscope image of fluorescent encoding beads 
non-covalently attached to the surface of a large support bead. (Right) Transmission electron 
microscope image 72.
Microcarriers can be also optically encoded by incorporating distinct proportions of 
different fluorescent dyes. This “color encoding” 73,74 strategy is indeed successfully used in 
Xmap technology (for multiplexing purposes in diagnostics) in which 5 µm sized polystyrene 
beads are internally loaded with precise proportions of red and orange organic dyes or 
quantum dots 45. However, compared to the digital information as written in Memobeads, 
the code in both colloidally encoded microcarriers and “multicoloured” microparticles is far 
more limited in capacity to store information on a specific drug.  Encoding by spatial 
selective photobleaching, at the other hand provides for a virtually unlimited number of 
unique codes.
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Decoding of Memobeads incorporated in tablets is in principal not very difficult. 
Clearly, dissolution of the tablets and subsequent centrifugation or filtration on a suitable 
membrane is sufficient to recover the Memobeads from the tablets. Subsequently, a simple 
fluorescence microscope (equipped with a pseudo-confocal module which allows imaging of 
the middle plane of the beads where the code is written; see Fig. 2) and a weak magnetic 
field at the microscope table would allow technicians to decode the beads. Memobeads are, 
however, also suited for the in-drug labeling of oral dosage forms other than tablets (like 
capsules, drug suspensions, drug solutions,….) and topical dosage forms (like creams, 
ointments,…) as long as they are compatible with the conditions during production. Clearly, 
Memobeads are not suited for the in-product labeling of injectables; 40 µm sized particles 
are too large and will block the microcapillaries in e.g. the lungs. Also, as they are large and 
not biodegradable, they would not be excreted by the kidneys and would thus accumulate in 
the body.
CONCLUSION
By spatial selective photobleaching (digitally) encoded micron-sized beads can be 
created. We have shown that Memobeads can be easily incorporated in tablets by 
compression of either Memobead-containing drug granules or a drug powder mixture 
containing Memobeads. Especially, the dot codes in the Memobeads did not deform during 
tabletting even when high compression forces were applied. Also, the permanent magnetic 
coating surrounding the Memobeads withstands the compression forces, a necessity for 
proper orientation of the beads at the time of readout. 
Compared to other types of optically encoded microcarriers, Memobeads have a 
number of assets for in-tablet labeling. Compared to multicolored microparticles, encoding 
by spatial selective photobleaching has the advantage of being able to provide a virtually 
unlimited number of unique codes, an obvious advantage considering the huge number of 
pharmaceuticals which are at risk of being counterfeited. Compared to colloidal encoding, 
which makes use of nanometer sized beads for encoding; the relatively large Memobeads 
have the advantage that the risk of becoming absorbed after oral intake by the gut is 
minimal. Also, as argued above, ingestion of Memobeads is highly unlikely to be toxic for 
humans. The styrene (monomer) and styrene oligomers mass in 100 beads (assuming 100 
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beads are taken daily) is expected to be less than 0.05 µg which equals the quantity 
tolerated in 2.5 ml of drinking water. The total mass of chromium dioxide in 100 beads is less 
than 1 µg, corresponding to the amount tolerated in 20 ml of drinking water. Also, the 
fluorescent dye is not expected to be toxic as it is fully immobilized in the polystyrene matrix 
and will thus not be released from the Memobeads in the gastrointestinal fluids. 
Counterfeiting of drugs is a real threat to public health in both developing as well as 
the industrialized countries. While probably all anti-counterfeiting technologies can be 
circumvented, the encoded particles described in this paper may help in combating 
counterfeit manufacturers who are becoming increasingly sophisticated in the use of high-
tech systems. Decoding Memobeads is not too difficult. However, encoding the beads, at a 
sufficiently high speed (i.e. > 10 000 beads a second) requires an extremely high degree of 
skill, equipment and know-how which should discourage counterfeiters.
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SUMMARY
The development of highly efficient and functional gene transfection techniques is 
important for both therapeutic objectives as well as a research tool in molecular biology. 
Nucleic acids can be delivered alone (naked nucleic acids) or can be packaged using viral or 
non viral vectors. Although viral vectors are currently the most efficient tool for gene 
transfer into cells, there are a number of problems associated with the use of these vectors. 
Therefore, there is increasing interest in non viral gene delivery which necessitates safe and 
efficient (non viral) vectors. In this framework, chapter 2 of this thesis evaluates two types of 
cationic hydroxyethylcellulose for gene delivery purposes. 
Immobilizing DNA to a supporting surface prior to cell seeding, instead of adding the 
DNA to cells already cultured on a support (bolus addition) has been proposed as a 
mechanism to improve the transfection efficiency. This “reverse transfection” method is at 
the basics of the so named “reversely transfected cell microarray” which may become a 
powerful tool for high-throughput screening of gene function in vitro. In this framework,
chapters 3 and 4 of this thesis evaluate the immobilization of nucleic acids and cells to 
photophysically encoded microcarriers.
In Chapter 1 we overviewed different nucleic acid delivery systems. “Reverse 
transfection” and the use of this method for high throughput screening of gene function in 
vitro were reviewed. Additionally several strategies were discussed to immobilize nucleic 
acids on solid surfaces. We described the LbL technique and the use of this technique to 
immobilize nucleic acids on solid surfaces. Digitally encoded microparticles with LbL coating 
and their possible use as non-positional microarray in multiplexing assays were introduced 
as well.
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In Chapter 2 the cationic hydroxyethylcelluloses PQ-4 and PQ-10 were evaluated for 
gene delivery. PQ-4 and PQ-10 were previously characterized in detail and already have 
applications in cosmetics and drug delivery devices for topical applications. Size distribution 
and surface charge properties of the nucleic acid/ cationic hydroxyethylcellulose polyplexes 
were determined by DLS and zeta potential measurements.The complexation of pDNA to the 
cationic polymers and dissociation of the polyplexes by polyanions (dextran sulfate or poly-L-
aspartic acid) were studied by gelelectrophoresis and the picogreen fluorescence assay.
Transfection efficiencies using COS-7 cells were evaluated by using the SEAP assay. The cell 
viability towards the polyplexes was determined using EZ4U assay. Their DNA binding and 
transfection properties were compared with the branched and linear polyethylenimie (PEI) 
which are widely investigated for DNA delivery purposes. Gelelectrophoresis and 
fluorescence experiments indicated that PQ-4 and PQ-10 indeed can bind and condense 
pDNA. Compared to PEI, the interaction between pDNA and cationic HEC seems to be 
stronger. Although, the gelelectrophoresis data showed that PQ-10 binds all the pDNA, the 
fluorescent quenching assay indicates that PQ-10 does not condense pDNA as tightly as the 
other cationic polymers, still allowing picrogreen to intercalate to a certain extent in the 
pDNA.
We found that PQ-4 and PQ-10 based pDNA complexes show low toxicity as more 
than 90% of the cells remain alive. However, compared to PEI based polyplexes, transfection 
of cells by cationic hydroxyethylcellulose is significantly lower which was, highly likely, due to 
a too strong complexation with the nucleic acids (for PQ-10) and an non-efficient uptake of 
the complexes by the cells (for PQ-4).
In drug screening and molecular biology people are interested to evaluate the activity 
of compounds in different types of cells. On the other hand performing multi-parametric and 
multiplexed assays provides significant advantages to singlet assays such as reduction of 
technical operation, execution time and over all costs. For this purpose “cell microarrays” 
are under development. In a “positional cell array” cells are grown at specific locations on a 
chip: from the x,y-coördinates of the place on the chip a particular cell is growing one knows 
which cell type it is. In Chapter 3 we proposed to develop a “non-positional cell array”, using 
photophysically encoded microcarriers (“Memobeads”); each of these encoded 
microcarriers can accommodate one cell type, the code in the carrier allows to identify the 
cell type growing at the surface of the carrier. 
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Codes were written inside fluorescent polystyrene beads by selective 
photobleaching. To make the polystyrene beads magnetic (necessary for encoding and 
decoding) and to provide them with a surface suitable for cell growth, the encoded 
polystyrene microspheres were coated by Layer-by-Layer technology with suitable 
polyelectrolytes. The cell loaded microspheres were decoded using a confocal laser scanning 
microscope.
The encoded beads did not show significant toxicity and several cell lines such as 
CHO, Vero, Hela and COS-7 could be grown on the beads. Importantly, the cells covering the 
beads did not hamper the decoding of the beads: they still permitted the magnetic 
orientation of the memobeads at the time of read-out. Fluorescence present in the cells 
(due to the expression of fluorescent proteins) did not hamper the decoding of the encoded 
beads. Furthermore, in Chapter 4 we have shown that the polyelectrolytes at the surface of 
the encoded microcarriers are suitable for immobilizing DNA, siRNA and adenoviral particles;
subsequently, on top of the immobilized nucleic acids/viral particles cells can be grown. We 
further showed that adenoviral vectors immobilized on encoded microcarriers maintain their 
ability to infect cells (reversed transfection) and the cells growing on the polyelectrolyte 
layer can become transduced with adenoviral particles hosted by the polyelectrolyte layer.
In addition, the adenovirus-coated microparticles have demonstrated to be stable and, 
importantly, the adenoviral particles only transfect those cells which are at the surface of 
the carrier on which the viral particles are immobilized. 
Another innovative application for the photophysically encoded microcarriers is 
described in Chapter 5 where we recommend to use them for the “in-product labelling” of 
tablets to avoid counterfeiting. Counterfeiting of drugs is a real threat to public health in 
both developing and industrialized countries as patients may become treated with drugs of 
inferior quality. “In-drug labelling”, i.e. the labelling of the drug instead of the packaging, 
would be a major step forward to combat counterfeiters.
The Memobeads were incorporated in tablets either by compression of Memobead 
containing drug granules or by direct compression of a drug powder/Memobead mixture.
We showed that the codes in the Memobeads in tablets produced by granulation did not 
deform during tabletting. Even when the granules were compressed at higher compression 
forces the Memobeads remain spherical and, especially, the code did not deform and 
remained perfectly readable. In tablets produced by direct compression the code in the 
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beads seemed to become destroyed when higher compression forces were applied. We also 
found evidence that, after oral intake, the encoded microparticles are highly unlikely toxic to 
humans.
GENERAL CONCLUSIONS
The first goal of this thesis was to investigate the potential of two cationic 
polysaccharides (PQ-4 and PQ-10) for DNA delivery. We have shown that, compared to PEI 
based polyplexes, they were less efficient in transfecting cells. However, as they had very 
low toxicity, further tailoring of the nature and extent of cationic side chains on cationic 
hydroxyethylcellulose may be a promising avenue to further enhance their DNA delivery 
properties.
As a second goal we investigated the applications of digitally encoded microcarriers 
for cell based assays. We succeeded to show that encoded microcarriers were suitable to 
grow cells on. Nor the coating at the surface of the beads (which facilitates the growth of the 
cells), neither the cells themselves hampered the decoding of the beads, even when the cells 
covering the microcarriers exhibited green or red fluorescence due to the expression of GFP 
and RFP respectively. We were able (a) to immobilize DNA, siRNA or adenoviral particles on 
the surfaces of the encoded microcarriers by the use of polyelectrolytes and, subsequently,
(b) to grow cells on top of the nucleic acids/adenoviral particles. The DNA and siRNA 
immobilized on the surface of the microcarrier were not able to transfect cells. However, we 
showed that the cells growing on the polyelectrolyte layer could indeed become transduced 
with adenoviral particles hosted by the polyelectrolyte layer. In conclusion, a proof of 
principal to use photophysically encoded microcarriers as transfected cell microarray has 
been shown. 
As a third goal we investigated the use of digitally endoced microcarriers as tool to 
combat counterfeiting of tablets. We showed that the codes in the Memobeads in tablets 
produced by granulation did not deform during tabletting and that the code in the beads 
remained readable. We also found evidence that, after oral intake, the encoded 
microparticles are highly unlikely toxic to humans.
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SAMENVATTING
De ontwikkeling van efficiënte en functionele gentransfectie technieken is enerzijds
belangrijk vanuit therapeutisch standpunt en anderzijds als werkmiddel in moleculair
biologisch onderzoek. Het toedienen van nucleïnezuren kan ofwel via naakte nucleïnezuren 
gebeuren ofwel kunnen deze ingepakt worden door gebruik te maken van virale of niet-
virale vectoren. Hoewel virale vectoren de meest efficiënte dragers zijn die momenteel 
beschikbaar zijn voor de afgifte van DNA in cellen, brengt het gebruik van deze vectoren 
verscheidene problemen met zich mee. Er is dan ook een stijgende interesse in de 
ontwikkeling van veilige en efficiënte (niet-virale) gen afgifte systemen. In deze context 
werden in het eerste deel (hoofdstuk 2) van deze scriptie twee types van kationische
hydroxyethylcellulose polymeren geëvalueerd als gen afgifte systemen.
Het immobiliseren van DNA op een drageroppervlak vόόr het uitzaaien van de cellen 
in plaats van het DNA toe te voegen aan cellen die vooraf in cultuur gebracht werden op een 
drager (bolus toediening) werd voorgesteld als een mechanisme om de transfectie efficiëntie 
te verhogen. Deze “omgekeerde transfectie” methode vormt de basis voor de zogenoemde 
“omgekeerd getransfecteerde cel microarray” dat een krachtige middel is voor het op grote 
schaal (high throughput) screenen van genfuncties in vitro. In deze context werd in het 
tweede deel (hoofdstuk 3 en 4) van deze scriptie het immobiliseren van nucleïnezuren en 
cellen op fotofysisch gecodeerde microcarriers geëvalueerd.
In Hoofdstuk 1 werd een overzicht gegeven van de verschillende nucleïnezuur afgifte 
systemen. “Omgekeerde transfectie” en het gebruik van deze in vitro methode voor high 
throughput screening van genfuncties werden meer in detail besproken. Daarnaast werd
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een overzicht gegeven van verscheidene strategieën om nucleïnezuren te immobiliseren op 
vaste oppervlakken, met nadruk op de in deze scriptie gebruikte laag-na-laag of LbL-
techniek. Ook digitaal gecodeerde micropartikels met LbL mantel en hun gebruik als niet-
positionele microarrays in mulitplex assays werden geïntroduceerd.
In Hoofdstuk 2 werden de hydroxyethylcellulose (HEC) polymeren PQ-4 en PQ-10 
geëvalueerd voor gen afgifte. Beide kationische polymeren werden vroeger reeds in detail 
gekarakteriseerd en kennen al verscheidene toepassingen in cosmetica en als geneesmiddel
afgifte systeem voor topicale toediening. Van de gevormde DNA/HEC polyplexen werden de 
grootte distributie en oppervlaktelading bepaald met behulp van DLS en zetapotentiaal 
metingen. De complexatie van pDNA met de kationische polymeren en de dissociatie ervan 
in aanwezigheid van polyanionen, zoals dextraansulfaat en poly-L-aspartaat, werden 
bestudeerd met behulp van gelelektroforese en een picogreen fluorescentie test. Vervolgens 
werd de transfectie efficiëntie en de cel viabiliteit geëvalueerd op COS-7 cellen via 
respectievelijk de SEAP en EZ4U assay. Als referentie werd gebruik gemaakt van vertakt en 
lineair polyethyleneimine (PEI), beide reeds uitgebreid bestudeerd en beschreven als 
afgiftesysteem voor DNA. Gelelektroforese en fluorescentie experimenten gaven aan dat 
PQ-4 en PQ-10 zoals verwacht in staat waren om te binden met DNA en het DNA bijgevolg te 
condenseren. In vergelijking met PEI bleek de interactie tussen pDNA en de kationische HEC 
polymeren sterker. Hoewel de gelelektroforese data aantoonden dat PQ-10 alle pDNA 
complexeert, blijkt uit de fluorescentie quenching test dat PQ-10 het pDNA minder sterk 
condenseert dan de andere kationische polymeren, aangezien picogreen tot op zekere 
hoogte nog steeds in staat is om in het pDNA te intercaleren.
We stelden vast dat de PQ-4 en PQ-10 gebaseerde pDNA complexen een lage 
toxiciteit vertoonden aangezien meer 90% van de cellen overleven. Ondanks deze 
bemoedigende resultaten bleken beide polymeren een significant lagere transfectie te 
vertonen in vergelijking met de PEI-gebaseerde polyplexen. Dit is hoogstwaarschijnlijk te 
wijten aan ofwel een te sterke complexatie met de nucleïnezuren, in geval van PQ-10, ofwel 
een inefficiënte opname van de complexen, in geval van PQ-4 polyplexen.
In geneesmiddelen screening en moleculaire biologie is men geïnteresseerd om de 
activiteit van bepaalde componenten in verschillende types van cellen te evalueren. 
Daarnaast leveren het uitvoeren van multi-parametrische en multiplexe assays significante 
voordelen t.o.v. singlet assays, waaronder een vermindering van het aantal technische 
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handelingen, van uitvoeringstijd en bovenal van kostprijs. Voor dit doeleinde zijn de 
zogenaamde “cel microarrays” in ontwikkeling. In een “positionele cel array” worden cellen 
gegroeid op specifieke plaatsten op een chip: aan de hand van de x,y coördinaten van de 
plaats op de chip waar de cellen groeien kan men afleiden over welk celtype het gaat. In 
Hoofdstuk 3 werd voorgesteld om een “niet-positionele cel array” te ontwikkelen door 
gebruik te maken van fotofysisch gecodeerde microcarriers of “Memobeads”. Hierbij kan
elke van deze gecodeerde microcarriers één celtype huisvesten, waardoor men vervolgens 
op basis van de aanwezige code, het celtype kan identificeren dat op het oppervlak van de 
Memobead groeit. Codes werden in de fluorescente polystyreen beads geschreven d.m.v. 
selectieve fotobleking. Om de polystyreen beads magnetisch te maken, wat noodzakelijk is 
voor het positioneren van de beads bij het coderen en aflezen, en om hen te voorzien van 
een geschikt oppervlak voor celgroei werden de gecodeerde polystyreen microsferen gecoat 
d.m.v. de LbL-technologie met de geschikte polyelektrolieten. Vervolgens werden de met 
cellen beladen microsferen gedecodeerd m.b.v. een confocale laser scanning miscoscoop. 
De gecodeerde beads vertoonden geen significante toxiciteit en verscheidene cellijnen, 
waaronder de CHO, Vero, HeLa en COS-7 cellijnen, konden gegroeid worden op het 
beadoppervlak. Een belangrijke vaststelling was dat deze cellen de decodering van de beads 
niet verstoorden aangezien de magnetische oriëntatie tijdens het aflezen nog steeds 
mogelijk was. Ook de aanwezigheid van fluorescentie in de cellen, veroorzaakt door de 
expressie van fluorescente eiwitten, verhinderde de decodering van de beads niet. 
In Hoofdstuk 4 werd bovendien aangetoond dat de polyelektrolietlaag op het 
oppervlak van de beads geschikt is om zowel DNA, siRNA als adenovirus partikels te 
immobiliseren. Vervolgens kunnen bovenop deze geïmmobiliseerde nucleïnezuren of virale 
partikels cellen gegroeid worden. Verder toonden we aan dat de geïmmobiliseerde
adenovirale vectoren op de gecodeerde microcarriers hun infectie eigenschappen behouden 
(“omgekeerde transfectie”) aangezien de cellen die groeien op de polyelektrolietlaag 
getransduceerd worden door de adenovirussen aanwezig in de elektrolietlaag. Daarnaast 
werd aangetoond dat de adenovirus gecoate micropartikels stabiel zijn en dat enkel de 
cellen die geïmmobiliseerd zijn op het oppervlak van de met virus gecoate bead 
getransduceerd werden.
Een andere innovatieve toepassing van bovenstaande fotofysisch gecodeerde 
microcarriers werd beschreven in Hoofdstuk 5 waar we voorstellen om deze beads te 
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gebruiken voor “in-produkt labelling” van geneesmiddeltabletten om namaak te voorkomen. 
Namaak van geneesmiddelen vormt een reële bedreiging van de publieke gezondheid in 
zowel ontwikkelingslanden als industriële landen aangezien patiënten door deze namaak 
risico lopen om behandeld te worden met geneesmiddelen van lagere kwaliteit. “In-drug 
labelling”, dit is het labellen van een geneesmiddel zelf in plaats van de verpakking, zou een 
grote stap voorwaarts zijn in de bestrijding van geneesmiddelen namaak. Hiervoor werden 
de Memobeads ingebouwd in de tabletten ofwel via compressie van de Memobead 
bevattende geneesmiddelgranules ofwel via directe compressie van een 
geneesmiddelpoeder/Memobead mengsel. We konden aantonen dat de codes in de 
Memobeads niet vervormd werden in de tabletten die bekomen waren via granulatie. Zelfs 
wanneer de granules met hogere druk behandeld werden behielden de Memobeads hun 
sferische vorm en werd de code niet vervormd of onleesbaar. Bij de tabletten gemaakt via 
directe compressie bleek de code vernietigd te worden wanneer hogere drukkrachten 
gebruikt werden. Daarnaast konden we ook aantonen dat de gecodeerde micropartikels na 
orale inname hoogstwaarschijnlijk niet toxisch zijn voor mensen.
ALGEMENE BESLUITEN
De eerste doelstelling van deze scriptie was nagaan of twee kationische 
polysaccharides (PQ-4 en PQ-10) potentieel hadden als DNA afgifte systeem. We konden 
aantonen dat beide polymeren in vergelijking met PEI-gebaseerde polyplexen minder 
efficiënt waren in het transfecteren van cellen. Ze vertoonden echter een lage toxiciteit, 
waardoor ze mogelijks wel geschikt zouden zijn voor gentherapie toepassingen na het 
verfijnen van de eigenschappen en lengte van hun kationische zijketens.
Een tweede doelstelling was het gebruik van digitaal gecodeerde microcarriers voor 
cel gebaseerde assays. We slaagden erin om aan te tonen dat de gecodeerde microcarriers 
geschikt waren om cellen op te groeien. Noch de coating op het oppervlak van de beads (wat 
de groei van de cellen vergemakkelijkt), noch de cellen zelf verhinderden het aflezen van de 
code, zelfs niet wanneer de cellen groen of rood fluorescent waren door de expressie van 
respectievelijk GFP of RFP. We waren bovendien in staat (a) om DNA, siRNA en adenovirale 
partikels op het oppervlak van de gecodeerde microcarriers te immobiliseren via het gebruik 
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van polyelektrolieten en (b) om cellen te groeien bovenop de geïmmobiliseerde 
nucleïnezuren of adenovirale partikels. Het DNA of siRNA dat geïmmobiliseerd werd op het 
oppervlak van de microcarriers bleek niet in staat om cellen te transfecteren. We konden 
daarentegen wel aantonen dat cellen die gegroeid werden op een polyelektrolietlaag die 
adenovirale partikels bevatte getransduceerd konden worden. Hiermee werd bewezen dat 
de fotofysisch gecodeerde microcarriers als “omgekeerd getransfecteerde cel microarray”
gebruikt kunnen worden.
Als derde doelstelling onderzochten we tenslotte het gebruik van digitaal gecodeerde 
microcarriers als middel om de namaak van geneesmiddelen te verhinderen. We konden 
aantonen dat de codes van de Memobeads in tabletten geproduceerd via granulatie niet 
vervormd werden en dat de code bovendien leesbaar bleef. Daarnaast vonden we ook 
bewijzen dat de gecodeerde micropartikels hoogstwaarschijnlijk niet toxisch zijn voor 
mensen na orale inname.
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 چكيده
 
تَظؼِ ٍ تكبهل اًتقبل شًي ثب كبرآيي ثبلا از اّذاف هْن در درهبى ٍ ّوچٌيي اثسار تحقيقبتي ثب ارزؼي در ثيَلَشي هَلكَلي هي 
. ثبؼذ
ٍيرٍظي )ٍ يب ثِ ـَرت ثعتِ ثٌذي ؼذُ در يك حبهل )اظيذ ّبي ًَكلئيك ثرٌِّ(اظيذ ّبي ًَكلئيك هي تَاًٌذ ثفَرت تٌْب
.  اًتقبل دادُ ؼًَذ )يب غير ٍيرٍظي
گرچِ در حبل حبضر ًبقل ّبي ٍيرٍظي هؤثرتريي ٍظيلِ در اًتقبل شى ثِ داخل ظلَل ّعتٌذ، هؽكلات ٍ هحذٍديتْبيي ثِ 
.  دًجبل اظتفبدُ از ايي حبهل ّب ٍجَد دارد
. ثِ ّويي ػلت تَجِ رٍز افسًٍي ثعوت حبهلاى شًي غير ٍيرٍظي ثراي اًتقبل ثي خطر ٍ هؤثر جلت ؼذُ اظت
ثراي اًتقبل شًي پرداختِ  )كبيتًَيك ّيذرٍكعي اتيل ظلَلس( در ّويي راظتب ففل دٍم ايي پبيبى ًبهِ ثِ ارزؼيبثي دٍ ًَع حبهل
.  اظت
ثر رٍي ظطح ”  ثر رٍي ظطَح قجل از كؽت ظلَلي، ثِ جبي اضبفِ كردى آى ثِ ظلَلْبيي كِ قجلاANDثِ تبزگي ثبثت كردى 
 كؽت ؼذُ اًذ ثِ ػٌَاى هكبًيعوي ثراي ثْجَد ًتيجِ اًتقبل شًي پيؽٌْبد ؼذُ، ايي رٍغ پبيِ تكٌيكي ثِ ًبم
 هي ثبؼذ كِ هي تَاًذ اثساري پر قذرت ثراي غرثبلگريْبي چٌذ گبًِ در ػولكرد شًْب  yarraorcim detcefsnart esreveR
ثِ دًجبل ايي ثحث در ففل ظَم ٍ چْبرم ايي پبيبى ًبهِ ثِ ثررظي ًحَُ ي ثبثت كردى اظيذ ّبي .  ثبؼذ ortivniدر هطبلؼبت 
. ًَكلئيك ٍ ظلَلْب ثر رٍي هيكرٍ حبهل ّبي كذدار پرداختِ اين
: ًوبيي از هطبلت تَضيح دادُ ؼذُ در ففَل هختلف ثِ ؼرح ريل اظت
ٍ  )noitcefsnart esreveR(دارد ثِ رٍؼْبي هختلف اًتقبل اظيذ ّبي ًَكلئيك، ّوچٌيي اًتقبل هؼكَض ففل يك ًگبّي
 ثؼلاٍُ در هَرد رٍؼْبي هختلفي كِ ثِ ortivniاظتفبدُ از ايي رٍغ ثِ ػٌَاى رٍؼي ثراي ظٌجػ ػولكرد شًْب در هطبلؼبت 
.  ثحث ؼذُ ٍاظطِ آًْب هي تَاى اظيذ ّبي ًَكلئيك را ثر رٍي ظطَح ثبثت كرد
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در ايي ففل ّوچٌيي .  ٍ اظتفبدُ از ايي رٍغ ثراي ثبثت كردى اظيذ ّبي ًَكلئيك ثر رٍي ظطَح تَضيح دادُ ؼذُLbLرٍغ 
  yarraorcim lanoitisop-noN پَؼػ دار ؼذُ اًذ ٍ اهكبى اظتفبدُ از آًْب ثِ ػٌَاىLbLهبيكرٍ ررات كذ دار كِ ثبرٍغ 
.  ثراي ظٌجػ ّبي چٌذ تبيي هؼرفي ؼذُ اًذ 
خفَـيبت ايي .  ثراي اًتقبل شى هَرد ثررظي قرار گرفتِ اًذ)01QP ٍ 4QP( كبيتًَيك ّيذرٍكعي اتيل ظلَلس ّب 2در ففل 
هب در ايٌجب اًذازُ ررات ٍ ؼبرش پلي . هَرد ثررظي قرار گرفتِ ” دٍ پليور كِ در ـٌبيغ دارٍيي ٍ آرايؽي كبرثرد دارًذ، قجلا
 تؽكيل كوپلكط ثيي ٍ laitnetop ateZ ٍ SLDپكلعْبي حبـل از تركيت آًْب ثب اظيذ ّبي ًَكلئيك را ثب كوك دظتگبُ 
ثَظيلِ  )دكعتراى ظَلفبت ٍ پلي اظپبرتيك اظيذ(پلكعْب ثب اظتفبدُ از پلي آيًٌَْب  ٍ كبيتًَيك پليورّب ٍ تفكيك پلي ANDp 
.  شل الكترٍفَرز ٍ ظٌجػ هيساى فلَر پيكَگريي هَرد ارزيبثي قرار گرفت
ظويت پلي پلكعْب ثب اظتفبدُ از .  اًجبم ؼذPAES ثب اظتفبدُ از ظٌجػ 7-SOCكبر آيي اًتقبل شًي ايي حبهل ّب در ظلَلْبي 
.  اًذازُ گيري ؼذU4ZE تعت
كِ  )dehcnarB-raeniL(،ثب حبهل ؼٌبختِ ؼذُ پلي اتيلي  ANDاًتقبل شًي ثَظيلِ ايي حبهل ّب ٍ ّوچٌيي اتفبل آًْب ثب
شل الكترٍفَرز ٍ آزهبيػ فلَرٍهتري ًؽبى هي دّذ كِ . ثطَر گعتردُ اي ثِ ايي هٌظَر هَرد هطبلؼِ قرار گرفتِ ، هقبيعِ گرديذ
 ثِ ًظر IEPايي اتفبل در هقبيعِ ثب .  را ثؼٌَاى يك حبهل دارا هي ثبؼٌذANDp تَاًبيي اتفبل ٍ فؽردُ كردى 01QP ٍ 4QP
ثبًذ ؼَد ٍلي ًتبيج ANDثب توبهي ” هي تَاًذ كبهلا01QP كِگرچِ ًتيجِ شل الكترٍفَرز ًؽبى داد . هحكن تر هي رظذ
ٍ اجبزُ هي .  را ثِ اًذازُ كبيتًَيك پليور ّبي ديگر ًذاردANDpتَاًبيي فؽردُ كردى  01QPفلَريوتري ًؽبى هي دّذ كِ 
 .  ًفَر كٌذANDp تب حذي ثيي ثبزّبي )neergociP(دّذ تب پيكَگريي
از ظلَلْب زًذُ هي % 09ٍ ثيػ از  ظويت ثعيبر كوي دارًذ AND ثب 01QP ٍ 4QPهب دريبفتين كِ كوپلكعْبي حبـل از 
قبثل هلاحظِ اي كوتر هي ثبؼذكِ ثِ احتوبل  ، اًتقبل شًي كبيتًَيك ظلَلس ّب ثِ طَر IEPثب پلي پلكعْبي  اهب در هقبيعِ هبًٌذ
 هي 4QP ٍ ػذم ًفَر كوپلكط ثِ ظلَل در هَرد 01QPزيبد ًبؼي از تؽكيل كوپلكط ثعيبر قَي ثب ًَكلئيك اظيذ در هَرد 
 . ثبؼذ
.  در پصٍ ّػ ّبي دارٍيي ٍ هَلكَلار، پصٍّؽگراى ػلاقوٌذ ثِ ارزيبثي اثر تركيجبت هختلف ثر اًَاع گًَبگَى ظلَلي هي ثبؼٌذ
ثبػث  )syassa telgniS( در هقبيعِ ثب ظٌجػ ّبي تكي  )syassa dexelpitluM(از طرفي اًجبم ظٌجػ ّبي چٌذ گبًِ
.   تَظؼِ يبفتٌذsyarraorcim lleCكبّػ ػوليبت تكٌيكي زهبى ٍ ّسيٌِ ّب هي ؼَدٍ ثِ ّويي هٌظَر 
 رؼذ هي كٌٌذ ، ّر ًَع ظلَل از هحل قرار گرفتي آى ثر رٍي ظطح  pihCكِ ظلَلْب ثر رٍي yarra llec lanoitisoP در 
را ثب اظتفبدُ از هبيكرٍ حبهل ّبي كذ دار yarra llec lanoitisop-noN  هب يك 3در ففل .  هؽخؿ هي ؼَدpihC
.  پيؽٌْبد كردين
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ّر يك از ايي ررات كذ دار هي تَاًٌذ جبيگبُ يك ًَع ظلَل ثبؼٌذ ٍ ّر كذ اجبزُ ؼٌبظبيي ظلَلْبي رؼذ كردُ ثررٍي ظطح 
.  حبهل را هي دّذ
.  ًَؼتِ ؼذُ gnihcaelbotohp evitceleSكذ ّب در داخل هبيكرٍ حبهلْبي پلاظتيكي فلَرظٌت ثب اظتفبدُ از تكٌيك 
ٍ فراّن كردى ظطحي هٌبظت ثراي رؼذ ظلَلي ايي هيكرٍ  )ثراي خَاًذى كذ ّب لازم اظت  (ثراي هغٌبطيعي كردى حبهل ّب 
.   ٍ ثب پلي الكترٍليتْبي هٌبظت پَؼػ دادُ ؼذُ اًذ LbLررات ثِ رٍغ 
.   ؼٌبظبيي هي ؼَدlacofnocظلَلْبي رٍي ّر هبيكرٍ ررُ از طريق خَاًذى كذ آى ررُ ثَظيلِ هيكرٍظكَح 
 هي تَاًٌذ 7-SOC ٍ aleH، OHC، oreVهبيكرٍ حبهلْبي كذ دار ظويت قبثل هلاحظِ اي ًؽبى ًذادُ ٍ اًَاع ظلَلْب هبًٌذ 
.  رٍي آًْب رؼذ كٌٌذ
لازم ثِ ركر اظت كِ ظلَلْبي پَؼبًٌذُ هبيكرٍ حبهل ّب هساحوتي ثراي خَاًذى كذّب ًوي ثبؼٌذ ٍ چرخػ آًْب در هيذاى 
.  هغٌبطيعي در زهبى خَاًذى كذ ٌَّز هيعر هي ثبؼذ
.  هساحوتي ثراي خَاًذى كذ ًوي ثبؼذ  )ًبؼي از تظبّر پرٍتييٌْبي فلَرظٌت(ّوچٌيي فلَرظٌت هَجَد در ظلَلْب 
 ٍ ANRis، ٍ AND هب ًؽبى دادُ اين كِ ٍجَد پلي الكترٍليت ّب در ظطح حبهل ّبي كذ دار ثراي ثبثت كردى 4در ففل 
.  ررات آدًَ ٍيرٍض هٌبظت اظت ٍ ثذًجبل آى ظلَلْب هي تَاًٌذ ثر رٍي اظيذّبي ًَكلئيك رؼذ كٌٌذ
اًتقبل (هب ًؽبى دادين كِ آدًَ ٍيرٍض ّبي ثبثت ؼذُ ثر رٍي هبيكرٍ حبهل ّبي كذ دار قذرت خَد را در آلَدُ كردى ظلَلْب 
.  حفظ كردُ ٍ هي تَاًٌذ در ظلَل ّبي رؼذ كردُ ثر رٍي پلي الكترٍليتْباًتقبل شًي ـَرت دٌّذ )هؼكَض
ثؼلاٍُ لايِ ررات آدًَ ٍيرٍض ًؽبى دادًذ كِ لايِ ايي ثب ثجبت ثَدُ ٍ تٌْب در ظلَل ّبيي كِ در ظطح حبهل ّب ّعتٌذ اًتقبل 
.  شًي ـَرت هي گيرد
 تَضيح دادُ ؼذُ كِ از آًْب ثؼٌَاى ثر چعت ّبي داخل 5يك كبرثرد جذيذ ديگر ثراي هبيكرٍ حبهل ّبي كذ دار در ففل 
.  هحفَل اظتفبدُ ؼَد تب ثتَاًين از تقلجْب پيؽگيري كٌين
تقلجبت دارٍيي يك تْذيذ جذي ثراي ظلاهت ػوَهي ثَدُ ٍ ثيوبراى چِ در كؽَر ّبي پيؽرفتِ ٍ چِ در كؽَر ّبي در حبل 
.  تَظؼِ هي تَاًٌذ هَرد درهبى ثب دارٍّبي ًبهرغَة قرار گيرًذ
در ايي رٍغ ثرچعت دارٍيي ثِ جبي قرار گرفتي رٍي ثعتِ ثٌذي دارٍ داخل دارٍ قرار هي گيردكِ هي تَاًذ قذم ثسرگي در راُ 
.  هجبرزُ ثب تقلجْب ثبؼذ
.   در داخل قرؾ ّبيي كِ از طريق گراًَلاظيَى يب فؽبر هعتقين ظبختِ ؼذُ ثَدًذ قرار گرفتٌذّب daebomeM 
 ّب، در قرؾ ّبي تَليذ ؼذُ ثَظيلِ گراًَلاظيَى ؼكل خَد را در طَل پرٍظِ ظبخت  daebomeMهبًؽبى دادين كذ ّبي 
 . قرؾ از دظت ًذادًذ
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.  ّب ثفَرت كرٍي ثبقي هي هبًٌذ ٍ كذّب تغيير ؼكل ًذادًذ daebomeM حتي زهبًي كِ گراًَلْب در فؽبر ثبلا فؽردُ ؼذًذ
هب ّوچٌيي ثِ ايي ًتيجِ رظيذين . در قرؾ ّبي تَليذ ؼذُ ثَظيلِ فؽبر هعتقين ررات كذ دار در فؽبر ثبلا تخريت هي ؼًَذ
.  كِ هفرف خَراكي ايي هبيكرٍ ررات كذ دار ثراي اًعبى ظوي ًوي ثبؼذ
 
 : نتيجه گيري كلي
 01QP ٍ 4QP ثَظيلِ دٍ كبيتًَيك پلي ظبكبريذ ثِ ًبم ّبي  ANDّذف اٍليِ ايي پبيبى ًبهِ تحقيق در هَرد تَاًبيي اًتقبل
.  ثَد
.   ايي پلي پلكعْبي جذيذ اثر كوي در اًتقبل شًي دارًذIEPهب ًؽبى دادين كِ در هقبيعِ ثب پلي پلكعْبي ثب هجٌبي 
 در  ANDٍلي از آًجب كِ آًْب ظويت خيلي كوي دارًذ تغييراتي در ظبختوبى آى هي تَاًذ ًَيذي ثراي ثْجَد تَاًبيي اًتقبل 
. ثؼٌَاى دٍهيي ّذف هب در هَرد اظتفبدُ از هبيكرٍ حبهل ّبي كذ دار در ظٌجػ ّبي ظلَلي تحقيق كردين . آًْب ثبؼذ
.  هب هَفق ؼذين ًؽبى دّين كِ هبيكرٍ حبهل ّبي كذدار ثراي رؼذ ظلَلْب ثر رٍي آًْب هٌبظت ّعتٌذ
ٍ ًِ خَد ظلَلْب ًوي تَاًٌذ هبًؼي ثرظر راُ خَاًذى  )كِ تعْيل كٌٌذُ رؼذ ظلَلْب ّعتٌذ  (ًِ پَؼػ ظطح هبيكرٍ حبهل ّب 
.  كذ ّبي رٍي حبهل ّب ثبؼٌذ
 را از خَد ًؽبى هي PFR ٍ PFGحتي زهبًيكِ ظلَلْبي پَؼبًٌذُ هبيكرٍ حبهل ّب، فلَرظٌت ظجس ٍ يب قرهس ًبؼي از تظبّرات 
 .دادًذ هب تَاًعتين كذ ّب را ثخَاًين
 ٍ ررات آدًَ ٍيرٍض ّب را ثر رٍي ظطَح هبيكرٍ حبهل ّبي كذ دار ثبثت كٌين ٍ ثذًجبل آى ANRisٍ AND  )هب تَاًعتين الف
.  ظلَلْب را رٍي ًَكلئيك اظيذ ّب ٍ ررات آدًَ ٍيرٍض رؼذ دّين  )ة
ثبثت ؼذُ ثر رٍي ظطح هبيكرٍ حبهل ّب قبدر ثِ اًتقبل شًي ًجَدًذ ٍلي هب ًؽبى دادين كِ در ظلَلْبي رؼذ ANRis ٍAND
. كردُ ثر رٍي ررات آدًَ ٍيرٍض ّب اًتقبل شًي ـَرت گرفتِ
.  ًؽبى دادينyarraorcim llec detcefsnarTطَر كلي هب اـَل اٍليِ اظتفبدُ از هيكرٍ حبهلْبي كذ دار را ثراي  ثِ
ثؼٌَاى ظَهيي ّذف در ايي پبيبى ًبهِ هب در هَرد اظتفبدُ از هبكرٍ حبهلْبي كذ دار ثراي هجبرزُ ثب تقلجبت دارٍيي تحقيق 
.  كردين
در قرؾ ّبي تَليذ ؼذُ ثَظيلِ گراًَلاظيَى در طَل هعير ظبخت . daebomeM,هب ًؽبى دادين كِ كذّبي هَجَد در 
هب ّوچٌيي ؼَاّذ يبفتين كِ هفرف خَراكي ايي هبيكرٍ حبهلْب ثراي اًعبى . قرؾ تغيير ؼكل ًذادُ ٍ قبثل خَاًذى هي ثبؼذ
.  ثِ احتوبل زيبد ثي خطر هي ثبؼذ
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